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Abstract to Thesis Portfolio 
 
Background 
With advances in medical treatments, the numbers of cancer survivors have grown 
considerably over recent years. Following completion of cancer treatment, patients 
can experience a range of physical and psychological difficulties, particularly 
around critical transition phases such as adjustment to survivorship. One of the 
most common difficulties cited by cancer survivors is that of fear of cancer 
recurrence (FOR). Existing treatments for improving psychological wellbeing in this 
population appear to offer limited efficacy, and there are very few interventions 
directly targeting FOR. Acceptance-based approaches, with an underlying aim of 
improving psychological flexibility, offer one novel alternative approach to 
addressing these difficulties.   
Methods 
This thesis presents a systematic review and meta-analysis of the literature in 
relation to the effectiveness of acceptance-based interventions for post treatment 
cancer survivors, with a particular focus on Mindfulness-Based Interventions (MBI). 
A cross sectional questionnaire study is then reported which explores the potential 
role of psychological flexibility in mediating the relationship between FOR and 
distress and quality of life (QoL)outcomes.   
 
Results   
The findings of the review offer tentative support for the effectiveness of MBI in 
reducing stress and depressive symptoms, while less convincing results emerged for 
anxiety. Results from the empirical study suggest that while psychological flexibility 
does not appear to significantly mediate the impact of FOR on distress and QoL, 
value based living and cognitive fusion did emerge as significant mediating 




Findings suggest that acceptance-based approaches, may be of benefit in reducing 
the burden of distress and improving the lives of cancer survivors. Supporting 
cancer survivors to become less entangled with their thoughts and live in 
accordance with their values may be particularly beneficial. Further studies using 
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The emotional impact of cancer is increasingly recognised, and with growing 
numbers of people living with and beyond the diagnosis, it is imperative to develop 
effective interventions to reduce the burden of psychological distress. Evidence 
suggests that existing interventions offer only limited benefits. In recent years more 
contemporary approaches focussing on acceptance and mindfulness have been 
tested in this population. While such approaches appear to offer promise, to date 
there has been little specific exploration of the effectiveness of these interventions 
with people adjusting to life following completion of cancer treatment. The current 
review therefore aimed to assess the evidence for the effectiveness of Mindfulness-
based Interventions (MBI) in post treatment cancer survivors.    
Methods 
A systematic search of the literature was conducted. Methodological quality of the 
studies was assessed, and both a meta-analytic and narrative synthesis of the main 
findings and limitations of the current evidence are presented.  
Results 
Eleven studies meeting criteria for inclusion were identified. Quantitative synthesis 
of the eight studies investigating Mindfulness-Based Stress Reduction (MBSR) and 
Mindfulness-Based Cancer Recovery (MBCR) interventions suggested the 
intervention to be helpful in reducing stress and depressive symptoms. The results 
were less convincing for effects on anxiety. Findings around the existence of a dose 
response relationship for MBI, and the role of changes in mindfulness in mediating 
intervention effects were mixed.        
Conclusions 
Though findings offer tentative support for the application of MBI in post treatment 
cancer populations, the relatively small number of studies identified and 
heterogeneity in measures used limit the conclusions that can be drawn from the 
13 
 
results. Future research to explore potential processes by which MBI effects are 
achieved are encouraged. 
Implications for Cancer Survivors 
The current review highlights the potential benefit of mindfulness-based 
interventions to promoting positive adjustment following treatment for cancer.  






















Distress in Cancer Patients 
In addition to a multitude of physical and practical challenges, it is increasingly 
acknowledged that being diagnosed with and treated for cancer has a significant 
emotional impact for many. Indeed, evidence from a large meta-analysis of existing 
evidence reported prevalence rates of clinical depression of between 8-24% among 
cancer patients both during and after treatment [1]. Clinical levels of anxiety appear 
to be similarly prevalent, with one large study of mixed cancer patients in Germany 
reporting 11.5% to be affected [2]. Interestingly, findings from a large survey of 
cancer patients within the UK, where patients were asked whether they considered 
themselves to have experienced anxiety or depression as a result of their cancer 
diagnosis, reported much higher figures: 75% of individuals reported difficulties 
with anxiety and 49% reported depression [3]. This suggests that in addition to 
individuals meeting clinical levels of distress according to validated measurement 
tools, there are likely to be many more experiencing adjustment difficulties not 
severe enough to trigger referral to specialist mental health services [4].  
For many patients, these psychological difficulties persist long after the completion 
of treatment, with some evidence suggesting that the risk of anxiety in particular 
remains higher in cancer survivors compared with healthy controls up to 10 years 
after diagnosis [5]. The consequences of this can be significant, with reported 
negative effects on quality of life (QOL), reduced engagement with medical care, 
and reduced survival [6]. While researchers have identified variations in levels of 
distress dependent on the measurement used, cancer type and treatment stage [1], 
taken together, this evidence highlights the importance of addressing the emotional 
impact of cancer.  
Interventions to Improve Psychological Outcomes in Cancer  
Over the years, a significant body of research has emerged investigating the efficacy 
of various psychological interventions aimed at reducing the burden of distress in 
cancer patients. Many studies have focussed on particular cancer types, with the 
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literature dominated by studies within breast cancer populations. A recent meta-
analysis of all psychological interventions aimed at improving psychosocial 
outcomes in post-surgical breast cancer patients found Cognitive Behavioural 
Therapy (CBT) approaches to be the most effective in reducing symptoms of anxiety 
and depression and improving quality of life [7]. However, pooled mean effect sizes 
reported by this review were small, and it is limited by its failure to define well 
specified descriptions of interventions, resulting in a wide range of treatment 
approaches being analysed together. Further systematic review evidence from 
studies involving prostate cancer patients [8] looked at individual/group CBT, and 
supportive-emotional interventions with patients at different stages of disease and 
treatment. The authors concluded that overall, such interventions appeared to have 
only small, short-term benefits on disease related aspects of QOL, and no 
statistically significant improvements in distress, depression or uncertainty. This 
review also identified a number of limitations to the studies reviewed, including the 
low quality of evidence, potential ceiling effects due to the inclusion of participants 
with generally high wellbeing, and uncertainty as to the clinical meaningfulness of 
observed intervention effects.   
Evidence from reviews of psychological interventions across cancer types offers a 
similarly mixed picture of their effectiveness. A meta-analysis of the effects of group 
therapy, counselling, education, and CBT by Newell and colleagues [9], concluded 
that the overall quality of existing studies was low, and only tentative support could 
be offered for their efficacy. In contrast, another review looking at both CBT and 
patient education interventions for cancer survivors found no evidence for the 
efficacy of the education interventions, but reported that CBT led to short term 
improvements in depression, anxiety and QOL, and sustained (>8months) 
improvements for QOL. They also reported greater efficacy for individual 
interventions relative to group interventions within the studies they reviewed [10].  
Another, more recent review by Faller et al. [11], looked at individual 
psychotherapy, group psychotherapy, psychoeducation and relaxation training in 
mixed cancer patients. They reported small to medium overall effects on emotional 
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distress, anxiety, and depression, which were all sustained at long term follow up 
for all interventions, with the exception of relaxation training where effects waned 
over time. 
Taken together, the evidence base for psychological interventions in cancer suggests 
that existing approaches such as CBT, psychoeducation and counselling 
psychotherapy offer only limited benefit for improving psychological wellbeing and 
QOL in this group of patients. There remain issues with the quality of the evidence 
available, and poor specificity around the nature of and active therapeutic 
ingredients of interventions. In addition, since these reviews more contemporary 
interventions have been investigated within this population. It is timely therefore to 
explore such interventions which take different therapeutic approaches, which may 
have the potential to offer increased benefits to psychological wellbeing for this 
patient group.  
Acceptance-Based Interventions  
With advances in anti-cancer treatments and increasing survival rates, cancer is now 
conceptualised as a chronic condition for many who are diagnosed [12]. This has led 
to growing recognition of the need to develop interventions aimed at optimising 
adjustment and helping those living beyond the disease achieve a good quality of 
life [13-14]. The existence of a range of physical and psychological sequalae 
following completion of treatment suggest the need for interventions with a focus 
on helping individuals to live well despite the adversities they are faced with. It is 
therefore appropriate that in recent years, acceptance-based therapies have been 
increasingly investigated within this population. Such therapies focus on 
willingness to experience difficult (or unwanted) sensations, emotions and thoughts, 
without striving to change them [15]. In this way, acceptance refers not to giving up, 
but to acceptance of the reality of present experiences, which in the context of cancer 
may include loss, pain or fears about cancer and death [16]. 
Though there exists a range of theoretically distinct therapeutic models under the 
umbrella of acceptance-based approaches, a central component shared by them all is 
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that of mindfulness. Mindfulness is a process of intentionally bringing conscious 
awareness of present moment experiences, with a non-judgemental accepting 
attitude [17]. Put most simply, mindfulness can be conceptualised as a way of being, 
but it can also be more formally practised through various meditation based 
exercises. Mindfulness meditation has its roots in Buddhism, but has been 
introduced as a secular practice within various psychological therapies as a tool for 
helping individuals increase awareness of the positive and negative experiences 
which are part of everyday human experience, and help them to respond to these in 
a more helpful way [18]. Increases in mindful awareness are proposed to increase 
positive affect, reduce negative affect and contribute to more adaptive coping 
responses [19].   
Recent evidence from a meta-analysis of the effectiveness of Mindfulness-based 
Interventions (MBI) with people who were physically unwell, people with 
psychological disorders, and non-clinical populations, reported large positive effects 
for anxiety and moderate effects for depression [20]. However, while the review 
found MBI’s to be more effective than psycho-education, supportive therapies, 
relaxation and imagery, it did not find it to be superior to CBT or behavioural 
interventions alone. In addition, there were moderate to high levels of heterogeneity 
within the studies included in the analysis. Therefore, while mindfulness 
interventions appear to offer promise for improving psychological wellbeing, 
further work is required to ascertain the relative efficacy offered by this approach 
over existing therapies.   
Mindfulness-Based Stress Reduction 
The most widely used standardised mindfulness intervention is that of 
Mindfulness-based Stress Reduction (MBSR). Developed in 1979 by Jon Kabat-Zinn 
[21], MBSR consists of a structured eight to ten-week mindfulness training program, 
delivered within a group setting. Weekly sessions generally last 2.5 hours and 
include instruction and experiential practice of a variety of mindfulness meditation 
exercises, including sitting and walking meditation, body scan meditation, and 
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yoga. Educational materials are also provided on stress and coping, relaxation, 
meditation and the connection between body and mind. Sessions also provide 
opportunities for group discussion, with an aim of sharing experiences and 
overcoming barriers to successful integration of mindfulness into everyday life. The 
program has a strong home practice element, with participants encouraged to 
practise mindfulness skills for a minimum of 45 minutes, six days a week. In 
addition, in its original form, MBSR typically offers a whole day intensive 
mindfulness retreat towards the end of the course [21].  MBSR has been applied 
within a variety of populations with an overall aim of relieving suffering associated 
with physical and emotional difficulties, through increasing openness and 
awareness [22].  
Mindfulness-Based Approaches in Cancer  
There has been growing interest in the application of MBSR within cancer 
populations over the last few decades. Alongside this a parallel cancer specific, 
mindfulness program, Mindfulness-based Cancer Recovery (MBCR), has been 
developed and tested. The intervention bears strong resemblance to the MBSR 
program, with a similar structured approach and use of mindfulness meditation 
training and home practise [23]. The program was developed to support patients 
following cancer diagnosis and during treatment, and was adapted from the MBSR 
format accordingly with patients’ physical health in mind. In practice, there appears 
to be little discernible difference in the two therapeutic modalities, and many 
studies purporting to use a MBSR intervention adapt the intervention accordingly 
for cancer populations. 
Evidence for Mindfulness-Based Therapy in Cancer 
Over recent years, increasing numbers of studies have been published investigating 
the effectiveness of Mindfulness-based Therapies with cancer populations. Again, 
much of the evidence base is dominated by research involving breast cancer 
patients, and a number of reviews of this evidence have been produced. Matchim 
and colleagues in their review of studies of MBSR, using mainly pre-post designs, 
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reported large effects on perceived stress and anxiety, and medium effects on 
reducing stress symptoms and overall mood disturbance [24]. Similarly, another 
meta-analytic review looking at controlled studies of both MBSR and MBCT 
reported small pooled effect sizes for depression and medium effects for anxiety 
[25]. A further meta-analysis reported moderate to large effect sizes for MBSR on 
outcomes of stress, depression and anxiety [26].  
Within mixed cancer populations, an early systematic review of controlled, 
uncontrolled and qualitative studies of MBI’s found good evidence to suggest their 
efficacy in reducing anxiety and distress, and mixed findings for their impact on 
depression [27]. Further evidence from a number of quantitative syntheses of the 
available evidence suggest similar promising effects. Ledesma et al [28] reported 
moderate effect sizes for improvements in mental health, and a smaller effect on 
physical health outcomes, while a further meta-analysis by Musial and colleagues 
[29] reported a small but positive overall effect on QOL, a small to medium effect on 
mood, and a medium effect on emotional distress.  
A notable limitation of these reviews is their inclusion of both Randomised 
Controlled Trials (RCT) and observational studies, and the grouping together of 
different aspects of psychological wellbeing in their analysis. This limits the 
conclusions that can be made about the relative effects of the intervention on 
different aspects of psychological functioning. In contrast, a meta-analysis by Piet et 
al [30] considered the effectiveness of MBSR and MBCT on anxiety and depression 
specifically, and reported moderate effect sizes on both outcomes. This review 
included both patients undergoing treatment and post-treatment survivors, but 
analysis did not distinguish the effects between the two groups, so no conclusions 
can be drawn about the impact of treatment status on findings. Despite this, a major 
advantage of this review was that it explored improvements in mindfulness 
following the interventions, reporting a small significant positive effect. This 
provides some evidence in support of the proposition that mindfulness mediates the 
improved anxiety and depression outcomes following MBI’s. More recently, a 
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further meta-analytic review of MBI’s which also specifically investigated the 
outcomes of anxiety and depression found significant effects for reducing 
symptoms of anxiety, and larger effects for depression [31]. However, as the authors 
highlighted, they did not account for the influence of cancer stage and severity of 
psychological symptoms at baseline, both of which could be usefully explored as 
potential moderating variables.   
Limitations of the Current Evidence for MBI’s in Cancer 
Though the growing interest in the application of MBI’s within cancer settings 
appears warranted, there are a number of limitations to the existing evidence base 
which limit the conclusions which can currently be drawn. Firstly, translating 
findings about the effectiveness of MBI’s to specific groups of cancer patients is 
challenging, as the majority of reviews have included patients at different stages of 
treatment, and many have included only breast cancer patients [24-26]. There is 
evidence to suggest that distress levels vary across the clinical course of cancer [32-
34], and intuitively, it could be argued that intervention targets may differ for 
patients who continue to undergo treatment compared to those who have 
completed curative treatment and are adapting to life as a cancer survivor. Indeed, 
there is some specific evidence to suggest the potential importance of the timing of 
MBI delivery. In their recent study of brief MBI versus relaxation within patients 
undergoing chemotherapy treatment, Reynolds and colleagues [35] reported that 
participants in the mindfulness group experienced an unexpected increase in 
physical symptom distress which was not observed in the relaxation group. In light 
of these findings, the authors caution against the use of mindfulness-based 
interventions, which can promote increased awareness of difficult physical 
experiences, during intensive anti-cancer treatment when there may be less 
opportunity for such practises to be maintained and supported.     
A further consideration which has been addressed by increasing numbers of studies 
but so far neglected within syntheses of the literature is around examining the dose 
response relationship, suggesting the ‘amount’ of a given psychological therapy 
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required to evoke clinically meaningful change [36]. Elucidation of this is 
particularly important given the current financial challenges faced by public sector 
mental health services in the UK, where in clinical practice interventions seek to 
deliver the greatest improvement for the least intensive input [37].   
Finally, it is of note that to date, studies exploring the effectiveness of MBI’s have 
largely focussed on the reduction of negative psychological symptoms, such as 
stress, anxiety and depression. While a valid aim and one which has been the 
scientific norm for a number of decades, this focus limits investigation of alternative 
benefits, such as increases in positive psychological outcomes [38]. This is 
particularly relevant when considering the application of acceptance-based 
interventions, which by their very nature move away from traditional attempts to 
‘get rid of’ unwanted emotional and physical experiences, focussing instead on 
moving towards achieving meaningful valued lives despite such experiences.     
Aims of the Current Review  
To date, no systematic review of the literature for acceptance or mindfulness-based 
interventions specifically in post treatment cancer survivors has been published. 
Though theoretical distinctions can be made between various acceptance-based 
therapies, they share an overarching focus on improving functioning in the context 
of difficult physical and emotional experiences, and a common shared component of 
mindfulness. In light of the limited evidence for the effectiveness of existing 
interventions, and the potential utility of this approach to meet the needs of the 
growing population of post treatment cancer survivors, it is timely to assess the 
evidence for such approaches in this review.   
The current review therefore aims to systematically examine the evidence for 
mindfulness-based interventions among post-treatment cancer survivors. 
Specifically, it aims to quantitatively summarise, using a meta-analytic approach, 
the effectiveness of such interventions on improving psychological outcomes of 
anxiety, depression, stress, cancer specific distress and fears of cancer recurrence. 
Two supplementary aims are to summarise the evidence for possible dose response 
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effects of the interventions, and to summarise the evidence for positive 
psychological outcomes. The amount of available data relating to these 
supplementary aims were predicted to be too small to allow quantitative synthesis, 
so a narrative synthesis was planned.  
Method 
Literature Search 
The procedure for conducting the review was guided by the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [39]. The 
search strategy was developed following an iterative process involving exploratory 
searches to establish the current state of the evidence base, and consultation with an 
expert librarian. Searches of The Cochrane Database of Abstracts of Reviews of 
Effects (DARE), and the International Prospective Register of Systematic Reviews 
(PROSPERO) were carried out before beginning the review, to identify any 
published or in process reviews of the same topic. None were found, confirming a 
gap in existing evidence for the current review topic. 
Final searches were run on the 25th May 2017, using databases selected according to 
the review question; EMBASE (1980 – 2017 week 21), PsychINFO (1806-May Week 3 
2017), Ovid MEDLINE (R) daily and Ovid MEDLINE (R) (1946 -present), CINAHL 
Plus, and the Cochrane Central Register of Controlled Trials (CENTRAL). The 
following search terms were used: mindful* or MBSR or MBCT or meditat* OR 
"acceptance-based" or "acceptance therap*" or "acceptance and commitment" AND 
“neoplasm*” or “cancer*” or “oncolog*” or “tumo*” or “malig*” or “haemat*” or 
“hemato*” or “leuk*” or “carcinoma*” or “melanoma*” AND “anxi*” or “depress*” 
or “distress*” or "affective disord*" or "mood disord*" or “stress” or “wellbeing” or 
"quality of life" AND “survivor*” or "post treatment" or "follow up".  
In an attempt to reduce potential publication bias as much as possible, a number of 
strategies were used to identify relevant grey literature. Firstly, the ProQuest 
Dissertations and Theses Global Database was searched for relevant dissertation 
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and theses abstracts, and web searches were conducted to identify other relevant 
unpublished dissertation or theses. Secondly, authors of protocols and conference 
abstracts were contacted to enquire about additional studies or unpublished results. 
Thirdly, a search of clinicaltrials.gov was conducted to identify any unpublished 
completed trials. Finally, the references of all identified papers meeting review 
criteria were screened for any additional papers. The review was restricted to 
English language papers only, due to limited resources, however attempts were 
made to contact authors of any non-English language papers to establish if a 
translated copy was available. 
Study Selection Process 
Selection of papers to be included in the review was aided by the use of a ‘PICO’ 
table; a method recommended for the development of a well-defined and precise 
review question. The PICO table covers the Population; Intervention; Comparator; 
and Outcomes of interest [40]. The PICO table developed for the current review is 
presented in Appendix 1. Search results were subject to review by the first author 
and in instances where there was uncertainty over study details, clarity was sought 
from authors by e-mail. To increase the reliability of the selection process, a random 
sample of 30% of full text records screened were second rated by a fellow doctoral 
student in Clinical Psychology with experience in Clinical Health Psychology 
research and practice (EB). Any discrepancies between ratings were resolved 
through discussion.   
Definition of Terms & Inclusion Criteria 
Definitions of the cancer survivor population differ widely, including; cancer 
patients from the day of diagnosis [41], all cancer patients and their immediate 
family members [42], or patients only from the point of completion of treatment 
until end of life [43]. Studies purporting to include cancer survivor populations can 
therefore encompass one of a number of groups depending on the definition used. 
For the purposes of inclusion in this review, cancer survivors were defined as 
individuals who had received a diagnosis of cancer and had completed primary 
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curative cancer treatment (those who continued to receive hormonal treatment were 
also included). 
This review was interested in what are often referred to as third wave therapies. 
Such approaches, described by Hayes as ‘Contextual Cognitive Behavioural 
Therapy’ (CCBT) “emphasize the context and function of psychological events more so than 
their validity, frequency, or form” [44, pp.141]. With this description in mind, a broad 
definition of mindfulness-based interventions was applied to include interventions 
with a standardised format such as Mindfulness-based Stress Reduction (MBSR) 
[21] and Mindfulness-based Cognitive Therapy (MBCT) [23]; Acceptance and 
Commitment Therapy (ACT) [15]; and other adapted interventions containing a 
core component of mindfulness.  
With these definitions in mind, studies were included according to the following 
criteria:  
• Inclusion of males and females, aged 18 years of over at the time of cancer 
diagnosis (no upper age limit) 
• Inclusion of participants who were post-treatment cancer survivors of any 
cancer type (no time limit post treatment)  
• Mindfulness-based interventions, i.e. interventions containing a central 
element of mindfulness 
• Aimed at improving psychological wellbeing and or quality of life or 
adaptive functioning following cancer treatment 
• Delivered by professionals with appropriate training and/or experience, and 
containing an interactive therapeutic component  
• Delivered in group or individual settings, face to face or via the internet or 
other technology media  
• Measuring at least one of the following psychological outcomes, using 
established validated measures carried out on at least two occasions (pre-
and-post intervention): Distress (e.g. anxiety and/or depression); Fear of 
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recurrence (measured using specific fear of recurrence measure); Positive 
psychological processes (e.g. post traumatic growth) 
• Studies utilising an RCT design, including one or more comparison groups 
Data Extraction & Coding 
The following data were extracted from the selected studies: Source details 
(published/unpublished, authors, year of publication, source of publication, 
country); sample size; population demographics (age, sex, cancer type, treatment 
type(s) received, time since diagnosis, treatment completion); setting in which 
recruitment took place; intervention description (including who delivered the 
intervention and details of any fidelity and adherence measures); study design; 
randomisation, blinding and control group details; attrition; outcome measures 
recorded and measurement time points; statistical analyses conducted; and 
summary of key findings.  
Quality Review 
The quality criteria developed for this review were established a priori, and were 
adapted from the Cochrane Risk of Bias Tool [45] and Scottish Intercollegiate 
Guidelines Network Critical Appraisal Checklist for Controlled Trials (SIGN 50) 
[46]. Criteria were selected based on their relevance to the review question, and 
contained eleven items on which studies were rated as ‘Well Addressed (+)’, ‘Poorly 
Addressed (-)’ or ‘Unable to say (?)’. Studies were not allocated an overall quality 
score, in line with current recommendations which suggest that weighting studies 
in this way may be misleading [40, 47]. Rather, descriptive overall quality ratings 
were given according to the degree to which studies met the pre-defined criteria, 
these were ‘High Quality ++’, ‘Acceptable Quality+’ and Low Quality 0’. Appendix 2 
presents the descriptive definitions outlining how each criterion was 
operationalised. All quality ratings were performed by the first author. In addition, 
in order to increase reliability of the process, a random selection of 36% of papers 
(n=4) were second rated by the same second-rater described earlier (EB). Initial 
inter-rater agreement was reached on 82% of quality criteria scores, indicating and 
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acceptable level of agreement. Any discrepancies were reviewed and resolved 
through discussion.  
Quantitative Synthesis of Main Findings 
All statistical analyses were conducted using the Quality Effects (QE) model within 
MetaXL [48]. This model incorporates weightings based on the quality assessment 
of studies, and was selected over the Random Effects models as it has been 
suggested to provide a more robust estimate of effect size and confidence intervals 
regardless of heterogeneity levels [49]. Published post intervention means and 
standard deviations for the variables of interest were entered into the analysis to 
produce standardized mean differences (SMD). Hedges g was selected as the effect 
size statistic, for its ability to allow comparisons between differing outcome 
measures by pooling variances [50]. In cases where the standard deviation was not 
reported, figures were calculated using confidence intervals [40]. Conventional 
effect size interpretations were used, with 0.2 representing a small effect, 0.5 a 
medium effect and 0.8 a large effect [51]. In two studies, there was more than one 
comparison group [52-53]. As the additional comparison groups could not 
intuitively be collapsed into either active intervention or no treatment control, two 
comparisons were made for each study between the mindfulness intervention and 
each of the control groups, with the total n of participants in the mindfulness group 
split and shared between the two groups [40]. The current review was focused on 
immediate intervention effects, therefore only immediate post treatment data were 
examined.  
Variability between studies was assessed using two established statistical methods 
for calculating levels of heterogeneity. Firstly, the p-value for the Cochran’s Q test 
statistic was examined, with significant p values suggesting the presence of 
heterogeneity between studies. As this test is known to have limited power in 
detecting heterogeneity, a cut off of p>0.1 was set for defining significance [54]. In 
addition, the I2 measure was used a further indication of heterogeneity. This 
provides an indication of the percentage of variation between studies due to real 
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difference rather than chance, and has the advantage of not being affected by the 
number of studies included within the analysis [50].  
Selective outcome reporting was assessed via the visual inspection of funnel plots, 
to identify the distribution of positive and negative effects for selected studies. 
Publication bias is indicated by the presence of a high proportion of effect sizes 
towards the bottom right hand side of the funnel plot [50]. Further statistical tests 
for asymmetry were not conducted (e.g. [55]) due to insufficient numbers of studies 





















































*See table 1 for list of exclusion reasons 
Records Identified through database 
searches: EMBASE, PsychINFO, 
Medline, CINAHL Plus & Cochrane 
CENTRAL  
 
n = 1,129 
Total records identified through searches  
n = 1,184 
Duplicates removed 
 
n = 580 
 
Total number of titles screened  
 
n = 604 
Screened out by 
title: not relevant 
n = 369 
 
Total number of abstracts screened 
n = 235 
Screened out by 
abstract 




 Total number of full text records 
screened  
n = 39 
Papers screened out 
by full text review  
n = 25 
Not post-treatment 
survivors n= 16 
Pure self-help, no 
interactive component 
n=1 
Not RCT n = 3 
Only reporting long term 
FU outcomes n = 2 





Number of papers accepted for 
inclusion n=14 
Other Records Identified 
N = 55 
ProQuest Dissertation & Theses Global n = 25 
Reference and hand searches n = 15 
Clinicaltrials.gov n=15 
 
Number of unique studies for inclusion 




Figure 1a. provides a flow chart summarising the study selection process. The 
combined searches identified a total of 1,184 records, of which 580 were excluded as 
duplicates and a further 369 were excluded by title as not relevant. This left 235 
records which were screened by abstract. For transparency, reasons for exclusion of 
papers by abstract are presented in Table 1a. At this stage, authors of protocols and 
conference abstracts where no published outcome paper was found were contacted 
by e-mail where possible. A full text screen was then carried out for records where 
abstracts indicated potential eligibility for inclusion (n=39), including cases where 
there was ambiguity around eligibility. The majority of papers were excluded at this 
stage due to inclusion of cancer patients during active treatment. A final selection of 
14 papers met criteria for inclusion in the review, describing 11 unique studies. Table 
2a. provides a summary of key information from each study.  
Table 1a. Reasons for exclusion of records by abstract  
Exclusion Reasons (n = 175) 
Not RCT 
Paediatric cancer patients 
Not cancer patients 
Participants currently undergoing primary treatment 
Advanced / metastatic disease  
No explicit mindfulness / acceptance component to intervention OR Mindfulness only minor 
element of intervention 
Intervention targeting specific symptom (e.g. cognitive impairment / sexual dysfunction / 
menopausal symptoms / insomnia / weight / diet / physical activity) 
No distress or QOL outcome measures 
Non-interventional study 
Qualitative results only  
Review paper 
Conference abstract only available (following e-mail to lead author to enquire about 
available unpublished data) 
Study protocol 





Table 2a. Summary of studies investigating the effectiveness of mindfulness-based interventions in post treatment cancer survivors  
Study Population  Setting  Intervention  Outcome 
measures 
Key findings  




N= 42 (28 MBCR, 14 Control) 
 





Mean Age 55 (MBCR) 57 
(Control) (range 36-79years) 
 
Time since treatment 
completion not reported 
(eligibility for inclusion - 





Group MBCR vs 
WLC 
 


















(SCS – short 
form) 
Results from t-test analysis: 
 
Anxiety increased in control 
group, decreased in MBCR 
group from pre-to-post 
(within group p=.07 ns).  
 
Data not reported for self-
compassion scale – short 
form 
 
Low to moderate correlation 
between home practice and 















coefficients and p values not 
reported) 
Main paper: 




Boyle et al. 
(2017) [58] 
 
N=71 (39 MAPS, 32 Control) 
 






























Results from linear mixed 
effects models analysis: 
 
Significant improvement in 
perceived stress in MAPS 
relative to control (p=.004 
effect size .67) Non-




Time since treatment 



















Mean total mins 
mindfulness 






















improvements in depressive 
symptoms (p=.095 effect size 
.54). 
 
Significant improvement in 
positive affect (p<.05 effect 
size not reported) and peace 
and meaning (p<.01 effect 
size not reported) 
 
No significant effect for 
cancer specific distress 
p=.385 ns, or fear of 
recurrence p=.128ns.  
 
Dose response analysis: 
Linear regression analysis 
revealed minutes of practice 























Significant indirect effects 
mediating path between 
intervention effect and 
depressive symptoms for 
rumination (β=-2.03(1.14), 
self-kindness (β=-
4.45(1.51), and mindfulness 
(β=-3.17(1.43). Within 
multiple mediation model – 
self-kindness remained as 
significant mediator (β=-
3.51(1.48). 
Only self-kindness mediated 









N=85 (32 MBSR, 39 Control) 
 
Mixed cancer types (76% 




Mean age 51.8 years (SD 9.86) 
 
Time since treatment 








Group MBSR vs 
WLC 
 
Face to face 
delivery 
 
Delivered by 2 
Clinical 
Psychologists 
trained in CBT 


























Results from MANCOVA 
analysis:  
 
Significant interaction time 
x group (F (7,60)=2.27, 
p<0.05) showing greater 
reduction in psychological 
distress and increase in 
positive states of mind in 
MBSR group relative to 
controls (effect size partial 
η2 = 0.21) . 
No significant main effect of 
time or group. 
 
Univariate tests showed 
significantly larger 



















60% - regular  
28% moderate 
12% - infrequent 
Mindfulness 
(FFMQ) 
on perceived stress 
(F(1,66)=8.79, p<0.01, 
partial η2 = 0.12 ), positive 
states of mind 
(F(1,66)=5.40, p=0.023, 
partial η2 =0.08) , and IES 
avoidance (F(1,66)=6.61, 
p<0.05, partial η2 = 0.09). 
 
Significant interaction time 
x group on mindfulness 
(FFMQ) (F(5,62)=3.45, 
p<0.05, partial η2 = 0.22). 
No significant main effect of 
time or group. Univariate 
tests showed significant 
time x group interactions 






greater pre-post increases in 
mindfulness in MBSR 
relative to controls. 
 
Mediation analysis (whole 
sample): Indicated that 
levels mindfulness mediated 
the effect of the intervention 
on perceived stress (β =
−0.23, p < 0.05), positive 
states of mind (β =
0.23, p < 0.05) and IES 
avoidance (β=-0.22, p<0.01) 
Carlson et al. 
Main paper (2013) [52] 
 
Secondary paper: 
Schellekens et al. (2017) [60] 
 
N=271 (113 MBCR, 104 SET, 
54 SMS) 
 





















Results from linear mixed 
models analysis: 
 
Significant group x time 
interaction for mood, small 
effect size (η2 =
37 
 
Canada   
Mean age 54.66 (MBCR) 53.62 
(SET) 56.27 (SMS) 
 
Time since treatment 
completion not reported (at 










delivered by staff 
with training 
and experience 































0.020, p<.05), however no 
significant difference 
between MBSR – SET 
(p=.024ns), or MBSR – 
SMS (p=.051ns) in pairwise 
comparisons 
 
Significant group x time 
interaction for stress, small 
effect size (η2=0.043, 
p<.05). Pairwise 
comparisons showed greater 
reductions in stress after 
MBCR (mean change -
19.30) compared with both 
SET (-9.46, p<0.05, and 
SMS (8.87, p<0.05). 
 















sub study as potential 
mediator. Results showed 
mindfulness did not 
increase significantly from 
pre to post intervention (F 
(1, 124) =.026, p=.872ns). 
Therefore no further 
mediation analysis on this 
variable performed. 




N= 229 (114 MBSR 115 
Controls) 
 




Mean (SD) age 49.0 (9.26) 
MBSR; 50.1 (9.14) Control  
 
Via charity run 







Group MBSR vs 
WLC 
 











Results of repeated measures 
ANOVA analysis: 
 
Significantly lower mood 
disturbance (total POMS) 
in MBSR group relative to 
controls at post intervention 
(p<.001). No significant 




Time since treatment 
completion Mean months (SD) 




















Dose related effect (multiple 
linear regression): increased 
hours of home practice were 
not significantly associated 
with improved mood at post 
intervention. 
Main paper:  
Lengacher et al. 




Group MBSR vs 
WLC 
State & Trait 
Anxiety 







Lengacher et al. (2014) [63] 
 
USA   







65 or older 27.4% 
 
Time since treatment 




















time (group + 
home): 18.0 (SD 
11.5) (data from 
n=39) 




















MBSR showed significantly 
better adjusted mean scores 
post treatment for state 
anxiety (p<.05), trait 
anxiety (p<.01), depressive 
symptoms (p<.01), fear of 
recurrence (p<.05), 
recurrence concerns (p<.01). 
F statistic and effect sizes 
not reported. 
 
No significant differences 
found for perceived stress or 
optimism. 
 
Dose response analysis 
(using general linear 























practice time was correlated 
with larger reductions in 
perceived stress (r=0.33, 
p<.05),  
An inverse relationship 
between minutes practiced 
and positive changes in 
optimism was found (r=-
0.32, p<0.05). 
 
Mediation analysis: fear of 
recurrence significantly 
mediated the effect of MBSR 
on perceived stress (z=2.12, 
p<.05) and state anxiety 
(z=2.03, p<.05).  
Lengacher et al. 
(2016) [64] 
N=322 (167 MBSR, 155 
Control) 
Three cancer / 
healthcare 















Mean age 56.6 (SD 9.7) 
 
Time since treatment 





































MBSR group showed 
significantly greater 
improvements in anxiety 
(d=.26, p<.05), and fear of 
recurrence (d=.30, p<.001) 
relative to controls.  
Trend for greater 
improvement in depressive 
symptoms for MBSR group 




effect of higher stress at 
baseline leading to increased 
improvement in fear of 











Dose response: no 
significant moderation effect 
of compliance on anxiety or 
fear of recurrence (p>0.05). 




N=62 (30 MBCR 30 WLC) 
 





Mean age (SD) MBCR 58 (8.2) 
Control 58 (13.0) 
 
Time since treatment 
completion not reported 


































Results of linear mixed 
models analyses: 
 
Significant time x group 
interaction (F (1,113) = 
3.95, p<.05) for total mood 
disturbance scores. 
Simple effects showed 
significantly reduced total 
mood disturbance scores for 
MBCR group relative to 




















Significant time x group 
effect for stress scores 
(F(1,113)=5.48, p<.01). 
Simple effects showed 
significantly reduced stress 
scores for MBCR relative to 
controls (d=.49, p<.01). 
 
Significant main effect of 
time for post traumatic 
growth (F (1, 113) = 19.69, 
p<.001). However, no 
significant difference 
between groups for increase 
in post-traumatic growth.  
 
Significant time x group 
interaction for mindful 
acting with awareness (F 
45 
 
(1,113) = 5.11, p<.05). 
Increased from pre to post 
for MBSR group (p<0.05). 
Main effect of time for all 
other subscale scores of 
FFMQ. 




N= 177 (66 MBSR, 57 Active 
Control, 54 Non-MBSR) 
 




Mean age (SD) 57.2 years 
(10.2) (range 34-80 years) 
 
Time since treatment 







Group MBSR vs 
Active Control 
(self-instructing 
MBSR) vs Non 
MBSR 
 





















parametric analyses for 
differences between and 
within groups: 
  
Significant within group 
improvements in depressive 
symptoms for MBSR group 
(mean 4.3(SD3.7) to 
3.3(3.3), p<0.01). 
 
Between group tests – 



















depressive symptoms in 
MBSR and active controls 
vs non MBSR (p<.05) 
Reduced ‘cases’ of 
depression (HADS D scores 
of 11-21) were 11% MBSR 
vs 8% in active controls and 
non MBSR. 
 
No significant within or 
between group effects for 
HADS anxiety. 
 
No significant within group 
effect for MBSR on coping 
capacity. However, MBSR 
ptpts showed significantly 
improved coping capacity vs 




Significant within group 
differences in MBSR group 
for ‘non-reactivity’ (2.9(0.7) 
vs 3.3(0.5), p<.001), and 
‘observe’ (3.3(0.7) vs 
3.6(0.5), p<.001) facets of 
mindfulness. Significant 
within group difference for 
active controls in ‘observe’ 
(3.3(0.7) vs 3.4(0.7), 
p<0.05).  
Significant between group 
difference between MBSR-
Active controls and non-
MBSR controls for non-
reactivity (p<.05), and 





Significant within group 
change in personal growth 
for MBSR group 
(59.78(19.5) vs 64.65(17.7), 
p<0.05). Significant 
between group difference 
between MBSR -active 
control vs non MBSR 
(p<.05).  




N= 49 (30 MM, 19 control) 
 




Mean age MM 66.1, Control 
64.8 (range 50-90) 
 
Word of mouth 
+ adverts in 










hour MM class 
at end of study) 
 
















effect on fear of recurrence 
(p<.05) and mindful 
attitude p<.05) 
 
All other variables non-
49 
 
Mean time since treatment 
completion not reported (at 





















minutes (SD):  












Weeks 5-8 – 52.5 
(86.0) 
Weeks 9-12 – 
42.6(76.6)  




N= 33 (16 CBCT, 17 Control) 
 




Mean age (SD) CBCT 54.7 
(12.1) Control 55.8 (9.7)  
 
Mean time since treatment 
completion not reported  
Breast cancer 
patients taking 









































Results of ANCOVA 
analyses: 
 
Significant reductions for 
CBCT group in depression: 
-3.7,95% CI (-6.3—1.1), 
p<.01), functional 
impairment scale of fear of 
cancer recurrence (-1.3, 
95% CI -2.5 - -0.1, p<.05) 
traumatic stress avoidance 
(-0.3, 95% CI -0.6—0.02, 
p<.05), and enhanced 
mindful presence (3.6, 95% 





























No other significant effects.  
 
 
Dose response: Significant 
inverse correlation between 
total practice time and fear 
of recurrence measure 
severity and distress scales 
(ρ=-0.65, 95% CI (-0.91, -
0.03) and ρ=-0.65, 95% CI 
(-0.91, -0.04) respectively). 




Note: CAMS-10= Cognitive and Affective Mindfulness Scale- Revised;  CARS= Concerns about 
Recurrence Scale;  CBCT= Cognitively Based Compassion Training; CES-D= Center for 
Epidemiologic Studies – Depression; C-SOSI= Calgary Symptoms of Stress Inventory; FACIT= 
Functional Assessment of Chronic Illness Therapy; FCRI= Fear of Cancer Recurrence Inventory;  
FFMQ= Five Facet Mindfulness Questionnaire;  FRQ= Fear of Recurrence Questionnaire;  GQ-6= 
The Gratitude Questionnaire;  HADS= Hospital Anxiety and Depression Scale;  IES= Impact of 
Events Scale;  LOT= Life Orientation Test;  MAAS= Mindful Attention Awareness Scale;  MAPS= 
Mindful Awareness Practices; MBCR = Mindfulness-based Cancer Recovery;  MBSR= Mindfulness-
based Stress Reduction; PANAS-PA= Positive and Negative Affect Schedule – Positive Affect; 
POMS= Profile of Mood States;  PSOMS= Positive States of Mind Scale;  PSS= Perceived Stress 
Scale;  PTGI= Post Traumatic Growth Inventory;  QLACS= Quality of Life in Adult Cancer 
Survivors;  RRS= Rumination Response Scale;  R-UCLA= Revised UCLA Loneliness Scale;  SCS= 
Self-Compassion Scale;  SET = Supportive Expressive Therapy;  SMS= Stress Management Seminar;  
SOC= Sense of Coherence Scale;  STAI= State-Trait Anxiety Inventory;  WLC= Wait list control 
Characteristics of Studies 
Intervention Type  
The majority of selected studies investigated the effectiveness of MBSR (n=5; 59, 61, 
62, 64, 53) or MBCR (n=3; 56, 52, 65) interventions. From the information provided 
within reports, both intervention types largely followed the same general format 
and content, with only slight adaptations being made to the original standardised 
programs [21,23]. All but two courses were eight weeks in duration, with the two by 
Lengacher’s group lasting only six weeks [62-63]. There was also slight variation 
within the length of classes. The majority of sessions lasted 2 hours, with the 
exception of Hoffman [61], where the first and last classes were 2.25 hours; Carlson 
[52] where all classes were 90 minutes; and Blaes [56] where classes were 2.5 hours. 
Only one of the MBSR studies contained an intensive mindfulness retreat [61], while 
all three MBCR classes included this feature [52, 56, 65]. 
The other three studies selected for review each investigated a different form of 
MBI. Bower and colleagues [57] investigated a Mindful Awareness Practice (MAPS) 
intervention, which was tailored for younger breast cancer survivors by the 
inclusion of information on health promotion and prevention of cancer recurrence. 
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The intervention was 6 weeks in duration with 2-hour long sessions, and covered 
comparable material to the standardised MBSR/MBCR programs including 
information about mindfulness and relaxation, experiential mindfulness-based 
exercises, psychoeducation, and group discussion around overcoming barriers to 
practice and managing difficult thoughts and emotions. Crane-Okada and 
colleagues [66] reported on a novel Mindful Movement intervention, which 
combined mindfulness training with dance/movement therapy to target increased 
body and mind awareness. Sessions took place over 12 weeks each lasting 2 hours, 
and involved both music and dance, mindful exercises, and group discussion 
around experiences and thoughts. In the third study, Dodds and colleagues [67] 
reported results from a Cognitively Based Compassion Therapy (CBCT) 
intervention with a sample of breast cancer patients. This intervention was 8 weeks 
in length, with 2 hourly classes. It incorporated experiential practical elements of 
mindfulness training with cognitive analysis of contributors to stress, with an 
emphasis on self-compassion.   
 All but one of the interventions [52] included in the review reported the inclusion 
of a homework element, incorporating experiential mindfulness exercises, reading, 
and reflective practice, with suggested duration of home practice ranging from 5 to 
45 minutes, 3 to 7 days a week. Four studies reported the use of formal measures of 
intervention fidelity, which included independent observation [62-63], use of a 
structured checklist [66], and video recording of classes [67]. Most studies also 
recorded participant adherence to the intervention, through number of classes 
attended and diaries logging home practice. Calculation and direct comparison of 
adherence rates was not possible across studies however, due to inconsistencies in 
reporting of this information.  
Design  
Most of the studies employed a two-arm, single centre, randomised controlled 
design. Eight involved a wait-list control condition, whereby participants continued 
to receive usual follow up cancer care and were offered the intervention on study 
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completion [56-59, 61-65, 67]. One employed a non-wait list ‘treatment as usual’ 
control group, who were offered a one off 3-hour intervention on study completion 
[66]. Only one study was multicentre [52], recruiting from similar settings across 
two major cities in Canada. Among the studies included in this review, only two 
encompassed an active control arm. Carlson et al [52] employed a three-arm design 
comparing MBSR with SET and a minimal treatment control group (Stress 
Management), while Sarenmalm et al [53] also compared three conditions of group + 
self-instructing MBSR, self-instruction only MBSR, and usual care control.  
Sample Characteristics  
The vast majority of participants recruited to selected studies were breast cancer 
survivors. Eight studies were aimed at only breast cancer patients, while breast 
cancer was the most prevalent diagnosis in the three mixed cancer studies. There 
was inconsistency in reporting of the length of time since cancer treatments had 
been completed.  Only three studies reported data on this variable [61-62, 64]. Four 
further studies specified a range of time points within their eligibility criteria but 
did not provide data on means (Blaes et al – within 6 months [56]; Carlson et al - at 
least 3 months [52]; Zernicke et al - within 3 years [65]; Crane-Okada et al - more 
than 12 months [66]). Time since diagnosis was reported for 6 studies, and ranged 
from less than one year to 10 years, with most participants being within the first 5 
years since diagnosis.     
Most studies reported information on cancer stage, with the majority including 
patients with stage 0-III disease only. Three did not report information on cancer 
staging [53, 56, 59], and two studies included some participants with stage IV cancer 
[65,67]. One study also reported some participants to have received their latest 
cancer treatment in relation to a recurrent cancer [61]. All but 3 studies [52,59,65] 
reported details of the nature of cancer treatments received by participants. The 
majority of participants included had received surgery, chemotherapy treatment, 
and radiotherapy treatment. Of the studies reporting detail of hormonal cancer 
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treatments [53, 57, 61, 64, 67], roughly half of the sample in each case had received 
such treatment.   
Only two studies screened potential participants for distress, in order that only 
individuals experiencing at least moderate levels of distress were included [52, 65]. 
Both studies utilised the Distress Thermometer [68] screening tool, specifying a cut-
off of four or higher to indicate eligibility for study entry. While this is a commonly 
used clinical cut-off, some have suggested that a score of six or seven might be more 
appropriate for its use as a single screen measure to identify distressed cancer 
patients [69]. 
Participants were recruited to studies from a variety of settings, using a range of 
methods. These included; media adverts and publicity within local newspapers or 
webpages [59, 52, 65, 66, 67]; cancer centres [52, 53, 56, 62, 64, 66, 67]; general 
healthcare centres [62, 64]; community outreach [52, 65]; and third sector support 
services and cancer patient organisations [61, 59, 66]. Some studies also used direct 
invitation methods, including; inviting potentially eligible participants from existing 
pools of research participants [57, 67]; physician referrals [57]; and direct mailing to 
potentially eligible participants via cancer registries [52, 65]. For studies recruiting 
from within clinical settings, there was insufficient information to establish whether 
the sample were purely self-selected or screened and notified of the study in some 
way. For studies employing a range of recruitment methods, there was no 
indication as to the relative numbers recruited via each method or setting to allow 
comparison of findings between groups. In three studies, participants were 
incentivised to participate with monetary or food voucher payments [62, 66, 67]. 
Sample Size & Power 
The sample size of selected studies was variable, ranging from 33 to 322, with a total 
of 1,411 participants included across studies. Seven studies had small to moderate 
sample sizes of <100 [56-57, 59, 62, 65-67], while four had large sample sizes of >150 
[52, 53, 61, 64]. All but one study [66] conducted an a priori sample size calculation, 
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and eight were sufficiently powered when accounting for final attrition rates [52-53, 
57, 61-62, 64- 65, 67].  
Attrition & Acceptability 
Study attrition rates were generally low. Four studies had attrition rates of >20%, 
although two of these were only marginally higher at 21% [56] and 20.4% [66]. 
However, six studies reported substantial differences in attrition rates between the 
intervention and control conditions, with a larger proportion of participants 
dropping out from the intervention arm than the control arm in all cases. This was 
generally not addressed by the study reports. Reasons for study drop out were only 
reported by a minority of studies and included: disease progression; other illness / 
health reasons; schedule conflicts; intervention not what was expected; being too 
busy; work; not wanting to be with other cancer patients; and moving away. 
Additionally, studies differed in how they defined successful completion of the 
intervention (e.g. minimum number of sessions attended), making rates of 
completion difficult to compare across studies. These issues limit the conclusions 
which can be drawn about the acceptability of the interventions to participants. 
Only two studies directly assessed participant satisfaction [65, 67], both reporting 
very high levels of satisfaction.       
Main Negative Psychological Outcome Measures  
Disturbed Mood & Stress: 
All selected studies included a measure of mood disturbance or distress, and there 
was relative homogeneity in the self-report measures utilised to assess this outcome. 
Three studies [52, 61, 65] used an overall measure of mood disturbance, the Profile 
of Mood States (POMS) [70]. The 65-item measure produces scores on six 
dimensions of anxiety; depression; anger; vigour; fatigue; and confusion, as well as 
a Total Mood Disturbance (TMD) score, produced by summing all dimension 
scores. Lower scores indicate less mood disturbance. All three studies used the TMD 
score in their analyses. The scale has been widely used within medical populations, 
including cancer patients [71], however has been noted to be a relatively lengthy 
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measure, which may be burdensome for completion within medical settings. A 
briefer short form has been developed which has been shown to have comparable 
psychometric properties to the original scale [72] however all three studies used the 
original measure.  
Three studies used the Hospital Anxiety and Depression Scale (HADS) [74] to 
measure symptoms of anxiety and depression independently [53, 59, 66]. This 14 
item questionnaire measures symptoms of anxiety and depression and was 
specifically developed for use within populations with physical illness. It contains 7 
items for anxiety and 7 for depression, each scored from 0 to 3, with a possible 
maximum score of 21 and total scale score of 42 for overall psychological distress. 
Higher scores indicate higher levels of anxiety, depression, and distress. The HADS 
is widely used in research and clinical practice, and has been shown to have good 
internal consistency and concurrent validity [75].  
Anxiety was measured using the State Trait Anxiety Inventory (STAI) [76] in three 
studies [56, 62, 64]. This measure assesses both current (state) and general long term 
(trait) anxiety levels using two subscales each containing 20 items, with higher 
scores indicating higher levels of anxiety. It is widely used in clinical research and 
has been shown to have good psychometric properties [77]. One study [62] utilised 
both subscale scores, while the others utilised only the State-Subscale [56,64].   
Depressive symptoms were measured using the Center for Epidemiological Studies 
– Depression Scale (CES-D) [78] in four studies [57, 62, 64, 67]. This 20-item measure 
assesses frequency of depressive symptoms within the past 7 days, with higher 
scores indicating greater depressive symptomology. It has been validated and 
shown to be a valid and reliable measure of depressive symptoms within cancer 
populations [79]. 
The majority of studies also included a measure of stress, and this outcome was 
most widely assessed using the Perceived Stress Scale (PSS) [80]. This is a ten-item 
scale which measures individuals’ perceptions of stressful life situations over the 
previous month, with higher scores indicating of higher levels of stress. The scale 
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has been widely applied in research including in cancer populations, and has good 
psychometric properties [81]. Four studies in the current review used the original 10 
item measure [57, 59, 62, 64], while one study used the briefer four item version of 
the scale (PSS-4; [80]) [67].  
Another measure of stress, used by two studies [52, 65], was the Calgary Symptoms 
of Stress Inventory (CSOSI) [82]. This measure contains 56 items measuring 
behavioural, psychological and physical responses to stressful situations. Subscales 
are combined to give a total stress score, with higher scores indicating increased 
levels of stress. It has been validated within cancer populations and found to have 
satisfactory internal consistency and good predictive validity [82].   
Risk of Bias & Quality of Studies 
Full quality criteria ratings for all studies can be found in Appendix 3, and are 
summarised in Table 3a. The quality of included studies was mixed. The overall 
quality rating of three studies was high [61, 64, 67], while four others were of 
acceptable quality [52, 57, 62, 65]. The remaining four papers were rated as low 
quality [53, 56, 59, 66]. Selection bias around the randomisation procedure used was 
generally well addressed, with most studies using a computer-generated 
randomisation sequence. Allocation concealment on the other hand was poorly 
addressed. Only five studies reported adequate allocation concealment procedures, 
with the remaining studies not addressing concealment in their report. As the 
included studies were all of group psychological interventions, full blinding of 
participants and researchers to reduce performance bias was not possible. However, 
three studies did address detection bias either by tasking a research assistant 
independent from the intervention delivery with collection of all outcome data [61], 
or by using online data collection methods [65, 67]. Of note, two of the papers 
scored as ‘unable to say’ in the risk of detection bias criterion reported blinding of 
outcome collection at baseline, but did not report any such details for post 
intervention. Therapist fidelity was also poorly addressed across studies, with seven 
papers not reporting any formal fidelity measures.  
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 Table 3a. Summary table of quality criteria ratings for reviewed studies 
Crane-Okada et 
al  
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Dodds et al  
 





Meta-Analysis of MBSR & MBCR Studies 
Although the search strategy employed aimed to review a range of mindfulness-
based intervention approaches within cancer survivor populations, eight out of the 
eleven studies selected for review were of standardised MBSR or MBCR 
interventions. There were insufficient numbers of other types of intervention to 
allow for a subgroup analysis by intervention type. Therefore, only the eight MBSR 
and MBCR studies were subject to meta-analyses, to ensure inclusion only of studies 
with sufficient similarity to allow pooled effect sizes to be calculated. From the eight 
studies, data on anxiety, depression, and perceived stress were extracted and used 
in the analyses. The other outcomes of interest (total mood disturbance, cancer 
specific distress/post-traumatic symptoms, and fear of recurrence) were insufficient 
in number or too heterogeneous in their measurement to allow them to be 
meaningfully included in the quantitative synthesis of findings.  
Results of the meta-analysis for anxiety outcomes, involving data from 833 
participants across 5 studies, revealed a small, non-significant pooled intervention 
effect size of -0.22 (95% CI -0.47, 0.04). The negative direction of the effect size 
indicates effects on anxiety in favour of the MBIs relative to controls. Indications of 
heterogeneity between studies were moderate, as demonstrated by a significant 
Cochran’s Q statistic (Q=10.78, p<0.10) and I2 statistic of 54%. Sensitivity analysis 
revealed that two studies, Sarenmalm (a and b) [53] and Hoffman [61] were 
contributing to the significant heterogeneity, with the I2 reducing to 37% when each 








Figure2a. Forest and Funnel Plots for Anxiety effects 
 
Note: Sarenmalm a= MBSR vs active control (self-instructing MBSR); Sarenmalm b= MBSR vs non-
active control (no MBSR) 
 
 
Results for the analysis of depression data, involving 822 participants across 5 
studies, revealed a small but significant pooled intervention effect size of -0.26 (-
0.46, -0.06). Again, the minus effect size denotes an effect in favour of the MBI 
condition.  In relation to this outcome, heterogeneity between studies was found to 
be insignificant (I2=35%; Q=7.69, p=0.17 ns), suggesting that effect sizes were all 
measuring similar effects. This suggests that overall the MBSR/MBCR interventions 
had a small beneficial decrease in depressive symptoms compared to control 
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  -0.09  ( -0.31,  0.13)     43.9
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Figure 3a. Forest and Funnel plots of effects for Depression 
 
Note: Sarenmalm a= MBSR vs active control (self-instructing MBSR); Sarenmalm b= MBSR vs non-
active control (no MBSR) 
 
Analysis of data from 384 participants across 4 studies revealed a small to moderate 
significant pooled intervention effect size for perceived stress (-0.45 (-0.66, -0.23). 
The direction of the effect is again in favour of increased benefits of MBI relative to 
control. Levels of heterogeneity between studies for perceived stress outcomes were 
very low (Q=2.63, p=0.62 ns; I2=0%). These findings indicate that of the three 
outcomes included in the meta-analysis, MBSR/MBCR had the most beneficial 
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Figure 4a. Forest plot of effects for Perceived Stress 
 
Note: Carlson a= MBCR vs SET (active control); Carlson b= MBCR vs SM (non-active control) 
 
Visual inspection of funnel plots for all three meta-analyses revealed approximately 
symmetrical distribution of effect sizes, suggesting low probability of publication 
bias.  
Narrative Synthesis of Additional Findings 
Dose Response Effects 
Six studies considered a possible dose response relationship between total 
mindfulness practice and psychological outcomes [56-57, 61, 62, 64, 67]. On balance, 
the evidence did not support the existence of such a relationship, with the three 
largest and better-quality studies failing to find a significant correlation between 
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overall mood [61], or fear of recurrence [64]. Only the study by Dodds et al [67] 
reported a large correlation between practice time and reductions in severity and 
distress of fear of recurrence. Three studies did report significant but small dose-
response relationships between practice time and reductions in anxiety [56] and 
perceived stress [62], however neither of these studies were of high methodological 
quality and both had relatively small sample sizes. Intriguingly, Lengacher et al [62] 
found an inverse relationship between practice time and optimism. 
Fear of Cancer Recurrence & Cancer Specific Distress 
The effect of the intervention on fears of cancer recurrence was addressed by five 
studies [57, 62, 64, 66-67]. Fear of recurrence has been identified as a common 
problem impacting on cancer survivors [83], however there is currently no agreed 
‘gold standard’ measure. Consequently, four different tools for assessing fear of 
cancer recurrence were used by the studies. Bower et al [57] used the Assessing 
Quality of Life in Adult Cancer Survivors (QLACS) [84]. Two studies used the 
breast cancer specific Concerns about Recurrence scale (CARS; [85]) [62, 64]. Crane-
Okada and colleagues [66] used the Fear of Recurrence Questionnaire [86]. Dodds et 
al [67] used the Fears of Cancer Recurrence Inventory (FCRI; [87]). Overall, findings 
suggested the mindfulness-based interventions to be effective in reducing fear of 
recurrence, with four out of the five studies finding significant effects [62, 64, 66-67]. 
Three of these studies were of acceptable or high quality [62, 64, 67].  
Cancer specific distress, also conceptualised as intrusive thoughts about cancer were 
reported as an outcome by three studies, two of which used the Impact of Events 
Scale [88] to measure the construct [57, 59], and one used the Impact of Events Scale 
revised (DODDS IES-R; [89]). The evidence for the effectiveness of MBI’s in 
reducing cancer specific distress appears mixed, with a high quality but small study 
by Dodds et al [67] and a moderate but low-quality study by Branstrom et al [59] 
reporting significant symptom reductions in this outcome. Meanwhile, Bower and 
colleagues [57] in their moderately sized study which was of acceptable quality 
found the intervention not to be effective in reducing post traumatic symptoms.  
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Positive Psychological Outcomes  
In addition to the negative psychological outcomes outlined above, a number of 
studies also reported positive psychological outcomes. The most relevant of these 
measures to the current review was mindfulness, which was reported by seven 
studies. The most frequently used measure of mindfulness was the Five Factor 
Mindfulness Questionnaire (FFMQ; [90]) (57, 59, 65, 66, 53], with other measures 
including the Mindful Attention Awareness Scale (MAAS; [91]) [66], Self-
Compassion Scale (SCS; 92]) [66], and Cognitive and Affective Mindfulness Scale – 
Revised (CAMS-R10; [93]) [67]. Four studies looked at the effect of the intervention 
on pre-to post changes in mindfulness scores between groups [53, 65, 66, 67]. 
Findings were mixed, with a general trend of increases in mindfulness pre-to post 
intervention, however in one study some improvements in aspects of mindfulness 
were also observed in the control group [65]. Only one of these studies was of high 
methodological quality, indicating that caution should be taken in interpreting the 
strength of the evidence suggesting MBI’s to improve mindfulness in this 
population. The other three studies conducted mediation analyses, to explore the 
role of changes in mindfulness in mediating the effect of the intervention [52, 58-59]. 
On balance, the evidence reviewed does not support the role of mindfulness in 
mediating the impact of the interventions. One study did report mindfulness to 
mediate effects on both reductions in perceived stress and cancer specific distress 
avoidance, and increases in positive states of mind, however this study was of low 
quality meaning this finding should be interpreted with caution [59]. Boyle et al [58] 
also found mindfulness to significantly mediate the effect of intervention on 
depression, however when considered among a range of mediating variables, self-
compassion was found to be a more influential mediator. In contrast, Carlson and 
colleagues [52] found that mindfulness did not significantly increase from pre-to 
post intervention, and was therefore not involved in mediating the effect of the 
intervention on outcomes.  
Of the other positive psychological outcomes, one large reasonable quality study 
found coping capacity and personal growth were significantly improved post MBSR 
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intervention relative to the control group [53]. Significant improvements were found 
pre-to post intervention in both positive affect and meaning and peace by [57], and 
significant increases in positive states of mind were reported by [59], however the 
sample sizes of these studies were relatively small and neither were of high quality. 
Based on three studies of reasonable or high quality, no significant intervention 




Overall, the findings from this review offer tentative support for the effectiveness of 
mindfulness-based interventions in ameliorating levels of perceived stress and 
depressive symptoms in post treatment cancer survivors. They therefore provide 
some endorsement for the proposed relevance of mindfulness-based approaches for 
helping patient find ways of living well in the context of the difficult physical and 
emotional sequalae they may face following treatment for cancer. The most 
encouraging findings were for reductions in perceived stress, while the evidence for 
anxiety was less convincing.  
Direct comparison of these findings with previous research is challenging due to the 
fact that many previous reviews have considered a range of different outcomes 
relating to psychological wellbeing. Of those specifically considering anxiety and 
depression however, the current review found smaller effect sizes for both outcomes 
than all previously published meta-analyses [25-26, 30-31], and a smaller 
intervention effect on stress outcomes [26]. The discrepant findings relative to 
existing reviews may in part be due to the small number of studies which met 
criteria for quantitative review. It may also be the case that inconsistency in findings 
reflects differences in the effectiveness of mindfulness-based interventions between 
patients with mixed treatment status and the specific post-treatment survivor 
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population. As the evidence base continues to grow, further review is recommended 
in order to elucidate this further.  
When considering the significant heterogeneity found within the meta-analysis 
analysis for anxiety, a few possible explanations for clinical diversity between 
studies in the analysis can be hypothesised. Firstly, the Hoffman [61] study involved 
only patients attending a third sector service attended by individuals for 
psychological support. Participants in this study may therefore have simultaneously 
been more psychologically distressed and more open to and ready to receive 
intervention, and therefore less representative of the overall sample of cancer 
survivors. Indeed, Hoffman and colleagues noted in their report that baseline mood 
disturbance levels were more severe than those reported in normative data and 
previous studies [61]. Furthermore, it is noted that within this analysis Hoffman was 
the only study in which the inclusion of a one-day intensive mindfulness retreat was 
retained from the standardised program, therefore the increased level of 
mindfulness training input may have further led to this sample being less 
representative of the clinical population as a whole.  
In relation to the Sarenmalm study, baseline anxiety scores were higher in the MBSR 
active intervention group than in both control groups [53]. Therefore, despite 
reductions in anxiety levels following the active intervention, mean scores remained 
proportionately higher relative to the control groups. Furthermore, the inclusion of 
an active control condition in the analyses introduces a comparison of a different 
nature, and therefore may introduce further heterogeneity, as the active control 
group consisted of a self-instructing MBSR group, which may be expected to 
experience more closely paralleled changes to the instructed group MBSR 
intervention. Finally, it is of note that compared to depression and stress outcomes, 
anxiety outcomes across all studies were measured with a wider variety of 
measures, which may also have increased overall heterogeneity. Further statistical 
exploration of heterogeneity was not possible using subgroup analysis or meta-
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regression due to the small number of studies, and caution should therefore be 
taken when drawing conclusions from these results. 
The current review also provides important information contributing to our 
understanding of the mechanisms by which MBI’s bring about improved outcomes 
in this population. Analysis of process measures was carried out by more than half 
of studies, most considering the potential mediating role of mindfulness. The 
findings were mixed for this variable, with not all studies found mindfulness to 
increase following intervention. In the Boyle et al study [58], mindfulness was found 
to mediate the effect of the intervention on depressive symptoms, however when a 
more complex model of mediation was considered, self-compassion was found to be 
a more influential mediator. This highlights the need for research to explore 
alternative pathways through which such interventions lead to improved outcomes. 
Within general mental health settings, a systematic review of evidence exploring 
such mediating relationships found the strongest evidence for MBSR effects being 
mediated via cognitive and emotional reactivity, moderate evidence for 
mindfulness, rumination and worry, and preliminary evidence for psychological 
flexibility [94]. Within cancer populations, one study providing useful insight into 
this question has also been conducted by Lengacher’s group [63], where they found 
support for a model in which MBSR led to reductions in fear of cancer recurrence, 
which mediated a range of psychological and physical health outcomes. In addition, 
a longitudinal dissertation study also with a cancer sample reported bi-directional 
mediating relationships whereby increased mindfulness and enhanced emotional 
regulation skills interacted to produce intervention effects on psychological 
outcomes [95]. Further exploration of potential mediating relationships will be key 
in shaping the development of MBI interventions targeted at specific cancer 
populations, through the identification of the key ingredients through which 
successful outcomes are achieved.  
Assessment of the overall quality of studies identified by this review suggests some 
caution should be taken in the degree of confidence we can have in the findings. 
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Weakness in methodological procedures were observed, particularly around 
allocation concealment and blinding of outcome collection, increasing the potential 
risk of bias to findings.  In addition, while overall study attrition was not 
problematic for the majority of studies, many reported significantly higher rates of 
attrition in the intervention group relative to the control group. Encouragingly, in 
most cases authors employed intention to treat statistical analysis intended to 
reduce the risk of bias, however it remains a potential additional source of bias to 
findings. Furthermore, only a few studies included a formal measure of fidelity to 
the intervention. It is therefore difficult to assess the exact nature and quality of 
intervention received by participants, and cannot be assumed that standardised 
MBSR and MBCR interventions were delivered in the same way across studies. On 
the other hand, it is also worth highlighting a number of areas of methodological 
strength identified across studies. The majority of studies were well powered, and 
randomisation procedures were well addressed and appeared successful based on 
the similarity of groups at baseline. Furthermore, measurement of participant 
adherence to the intervention, which has been previously highlighted as a neglected 
aspect of MBI studies [28] was found to be well addressed within the current 
review.  
Additional Findings 
A supplementary aim of the current review was to summarise the evidence for dose 
response relationships between mindfulness practice and psychological outcomes. 
Encouragingly, over half of the selected studies considered this as an outcome, 
however overall findings were mixed, with three studies finding no evidence of a 
significant dose response, and two finding only small correlations with amount of 
practice and reductions in anxiety [56] and perceived stress [62]. Neither of these 
findings were based on high quality evidence, however findings from Dodds and 
colleagues [67], which was rated as a high-quality study, did report large 
correlations between increased mindfulness practice and decreasing fear of 
recurrence. In view of the current pressures faced by clinical services, these mixed 
findings warrant further exploration, in order that evidence can inform the 
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development of efficient interventions which utilise the minimum intervention 
resource for the maximum patient benefit.  
An additional supplementary aim of the review was to explore the previously 
somewhat neglected area of positive psychological outcomes. A shift in focus from 
simply looking for reductions in negative outcomes, towards exploring potential 
positive impacts achieved by therapeutic interventions may be beneficial, as the two 
have been suggested to be related but discrete concepts [59]. Overall, limited 
conclusions can be drawn from the current findings about the effect of MBI’s for 
post-treatment cancer survivors on positive psychological outcomes, due to the 
significant variation in outcomes studied.  
With the continued expansion of the evidence base for mindfulness-based therapies 
in cancer, it would be beneficial for future research to take a more harmonious 
approach to the selection of relevant positive psychological outcome measures, in 
order that increased comparison across studies is possible. However, before this 
happens in practice, decisions will be required by researchers around choosing the 
most relevant outcome measures of interest. While the overall focus of acceptance-
based approaches is not on controlling or eliminating unpleasant internal 
experiences (such as anxiety or distressing thoughts) but rather to change the 
relationship an individual has with such experiences, it may be argued that a shift is 
required in the type of outcome measures traditionally employed to measure 
effective change (e.g. severity of depressive and anxiety symptoms). On the other 
hand, in order to establish the relative benefit of ACT based interventions over and 
above those which are widely used, such as CBT, it is important that comparisons 
are able to be made between the two approaches.  
One potentially overlapping outcome, which has often been studied in both 
traditional psychological therapies and which is consistent with a wider focus than 
simply elimination of distress, is that of QOL. However, quality of life as a concept 
is often poorly defined as a research outcome, and studies within clinically unwell 
populations such as cancer have employed a vast array of assessment measures and 
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definitions of the concept, making synthesis findings extremely challenging. Further 
work is therefore required in this area to allow the effective synthesis of future 
research findings.    
Limitations of Current Evidence & Areas for Future Research 
It is important to note that despite the original intention of the current review to 
include a broad range of acceptance-based interventions, the majority of 
interventions selected for review were of MBSR and MBCR. This finding in itself 
provides important information about the current state of the literature on more 
recently developed acceptance-based approaches within cancer survivor 
populations, such as Acceptance and Commitment Therapy (ACT).  Four studies of 
ACT interventions were retained for review at the full text stage, however none met 
final criteria, due to not utilising an RCT design [96-97], including cancer patients at 
different stages of treatment [98], or not being available in English [99]. Two of these 
studies were published in the last two years, suggesting a potential increase of 
interest in the application of ACT within this population. It is clearly too early to 
assess the evidence for the efficacy of such approach within post treatment survivor 
populations, however the encouraging findings of ACT studies in wider cancer 
samples (e.g. [96]) suggest the benefit of continued expansion of this research into 
survivorship.  
Another issue which is pertinent to the current review is that of possible floor effects 
due to the failure of most studies to screen participants for problematic levels of 
distress. Only two of the studies within the current review utilised this approach, 
which is in keeping with previous findings that psychological interventions in 
cancer populations generally do not specifically target those with distress [100]. 
While there is clear evidence that people experience a range of concerns after 
treatment completion, and that some require support, many patients are resourceful 
at self-managing and finding solutions themselves [101]. It has therefore been 
suggested that psycho-oncology interventions should be targeted specifically at 
those experiencing significant difficulties [100]. However, in line with the shift away 
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from eliminating negative symptoms towards a focus of living well, it may also be 
argued that acceptance-based interventions in particular have a place in helping all 
cancer patients to achieve more fulfilling lives following treatment. From this 
standpoint, interventions which aim to facilitate positive adjustment to cancer and 
offer preventative strategies to maintain good quality of life are of value [102]. This 
is an issue which has yet to be resolved, and has important implications for the 
assessment of efficacy of such interventions. No subgroup analysis between studies 
which screened for distress vs those which did not was possible within the current 
review due to low numbers. However, evidence from a meta-analysis of psycho-
oncology studies across all cancer stages identified that those recruiting only 
significantly depressed patients reported much larger effects on outcomes relative to 
those with no screen [11].   
Selected studies included mostly recent cancer survivors, consistent with findings 
from other authors that psycho-oncology survivorship research tends to focus less 
on longer term survivors [5]. This limits the extent to which the current findings can 
be applied to longer term cancer survivor populations, and no conclusions can be 
drawn about at what point in the post treatment survivorship pathway it might be 
best to introduce MBIs. In addition, the majority of participants within the reviewed 
studies were female breast cancer patients, limiting the generalisability of the 
findings to males and those with other cancer types. This is an issue which has been 
highlighted by other researchers in the field (e.g. [96]). It is important for research to 
be expanded to other cancer types and across age range and gender, in order to 
increase our understanding of potential adaptions which may be required for 
different groups (e.g. number of sessions, adapted content, or different timing in 
cancer journey). Evidence for how interventions may need to be tailored in this way 
comes from additional analysis of the reviewed study by Zernicke and colleagues 
[103], who found that younger participants experienced increased improvements in 
some outcomes compared to older participants, while males experienced increased 
post-traumatic growth over time relative to women.     
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A potential methodological limitation of the studies selected within the current 
review is that most employed a wait list control design. While such designs are 
extremely common in psychological research and have ethical advantages over, for 
example, a no treatment or placebo intervention control group, they do not allow 
researchers to control for non-specific effects of active intervention. Reliance on this 
design may therefore exaggerate the apparent effectiveness of the intervention. An 
alternative design using a ‘head to head’ comparison, where the relative efficacy of 
the intervention of interest versus an existing, evidence based intervention is 
assessed, has significant merit [104]. However, such designs are likely to require 
increased resources and costs to set up and run and, perhaps for this reason, within 
the current review only one study used a three-arm design with both active control 
and alternative evidence based therapy conditions for comparison [52].  
Limitations & Strengths of the Current Review  
There are a number of potential limitations to the current review. Firstly, a 
quantitative synthesis of findings was undertaken in light of the high levels of 
similarly between selected studies. However, the numbers of studies available for 
meta-analysis was low, and findings may therefore be subject to a higher risk of 
Type 1 error [105]. Secondly, an element of publication bias was introduced by the 
fact that it was not possible to include non-English language papers. This led to the 
exclusion of one paper which may otherwise have been selected for review [99]. 
Thirdly, the review was limited to considering only the immediate benefits of 
interventions. It would be beneficial for further work to be done to allow 
conclusions to be made about how well the observed effects were maintained into 
longer term survivorship. Finally, it was out of the scope of the current review to 
consider physical and biological outcomes in relation to MBIs in this population. 
There is however a substantial body of evidence on this topic and with recent 
tentative evidence from general population and mixed cancer stage patients 
suggesting potential beneficial impacts of MBIs on immune recovery [106], this field 
warrants further investigation.   
75 
 
There are also a number of strengths to the current review to be highlighted. This is 
the first known systematic evaluation of the evidence base for mindfulness-based 
interventions within the specific population of post-treatment cancer survivors. As 
outlined earlier, the explicit exploration of interventions for this stage of cancer is 
merited in view of evidence to suggest the particular prevalence of difficulties at 
this stage in the clinical course of cancer [34]. In addition, the explicit focus of the 
current review on randomised controlled trials sought to increase the quality and 
reduce the risk of bias of evidence considered. The inclusion of information about 
dose response and exploration of process outcomes also provide useful insights into 
the potential mechanisms by which such interventions may be effective. Aside from 
the necessary exclusion of non-English language papers, the review is also 
strengthened by the thorough attempts made to identify unpublished literature. 
Finally, where many existing reviews of psychological interventions for cancer 
patients encompass a very broad range of therapeutic interventions (e.g. [7]), the 
current review may allow for a more precise exploration by specifically focussing on 
interventions with a core component of mindfulness. This approach reduces the risk 
that findings may be diluted by heterogeneity between studies. As the evidence 
base for mindfulness-based approaches continues to develop, it will hopefully be 
possible to refine this still further, considering the relative strength of the evidence 
for distinct therapies with both acceptance-based and traditional CBT based 
approaches.  
Clinical Implications 
The National Institute for Clinical Excellence (NICE) guidelines on supportive care 
in cancer highlight the need to assess and treat psychological distress [107], and 
suggest a four-tiered service structure offering appropriate interventions dependent 
on the level of support required. While reference is made to CBT and psychotherapy 
within these guidelines, there are currently no national evidence based 
recommendations for the use of specific therapeutic approaches within cancer 
populations. Within a Scottish context, Psycho-oncology interventions are 
minimally covered within the MATRIX [108]. Where international guidelines exist, 
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they suggest that there is currently insufficient evidence for the relative advantage 
of one therapeutic modality over another, and therefore recommend selection of 
approaches to be based on individual patient factors and resources [109]. This 
highlights the requirement for the systematic synthesis of available evidence, such 
as presented in the present review, to ensure that patients are offered interventions 
based on the best currently available evidence.  
A key consideration in assessing the feasibility of mindfulness-based interventions 
for cancer survivor populations is the extent to which they are acceptable to patients 
themselves. Limited conclusions around acceptability can be drawn from the 
evidence reviewed. The two studies which formally assessed satisfaction both 
reported very high endorsement of the intervention [65, 67]. However, the finding 
that six studies reported substantially higher attrition rates within the intervention 
group points to the need for further exploration of potential barriers to engagement 
with mindfulness-based approaches. Only limited qualitive evidence of this nature 
exists [e.g. [110]), however within the UK, a study exploring the perceptions and 
potential barriers to mindfulness interventions is ongoing, and will provide 
important insights once complete [111].  
While significant advances have been made in recent years in increasing access to 
psychological therapies in general [37], there remain challenges to scaling up and 
adapting successful interventions delivered in research trials into actual clinical 
practice. In particular, researchers have highlighted that time constraints, staff 
turnover, and reduced intervention fidelity can pose barriers to the success of 
translating effective psychosocial interventions into real world clinical settings [112]. 
Maintaining intervention fidelity also requires to be balanced with achieving 
realistically flexible approaches which can be tailored according to individual 
formulations and applied in busy resource-constrained clinical settings. It has been 
argued that transdiagnostic approaches are particularly suited to achieving such a 
balance however, as they provide more flexible delivery while retaining a structure 
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for measurement [113]. Acceptance-based MBI’s which are largely transdiagnostic 
may therefore be more easily introduced than some other intervention approaches.     
One potential avenue for increasing the reach of MBI’s in this population is the use 
of media based delivery. The encouraging results reported by Zernicke and 
colleagues [65] in their online adaptation of an MBCR intervention may stimulate 
further work to explore media based platforms as an effective alternative to 
traditional face to face group delivery of this type of program. Smartphone 
technology offers further possibilities for expanding the reach of mindfulness-based 
interventions for cancer patients, and has been suggested to be acceptable and 
effective in a range of physical and mental health settings (Barker, unpublished 
doctoral thesis). Although large-scale rolling out of online or app based 
mindfulness-based therapies for cancer survivors would take considerable work 
and investment, it may offer possibilities for reaching a much larger proportion of 
the survivor population, who may otherwise be unable to access these interventions.  
Summary and Conclusions 
This review aimed to fill a notable gap in the literature by providing a 
comprehensive synthesis of existing evidence for mindfulness-based interventions 
in post-treatment cancer survivors. Overall, findings of the review suggest that 
mindfulness-based therapies such as MBSR and MBCR offer some benefit to this 
group of patients, particularly in reducing symptoms of stress, and to a lesser 
degree in reducing depressive symptoms. The review also highlights important 
directions in future research, particularly around further exploration of the 
pathways through which such interventions lead to change, and a shift towards 
greater consideration of positive psychological outcomes in future intervention 
trials. Methodological limitations to the selected studies were observed, and future 
studies would benefit from ensuring more thorough assessment of intervention 
fidelity and patient acceptability. Despite these shortcomings, the review suggests 
that the increasing application of mindfulness-based therapies has the potential to 
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offer a helpful approach to addressing the emotional impact of cancer for the 
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Evidence suggests that for people living with and beyond cancer, there are key time 
points in the trajectory at which psychological distress is most likely to occur. One 
such point is the transition from completion of treatment into survivorship, when 
fear of cancer recurrence (FOR) has been repeatedly identified as an unmet need for 
many. Consensus over the theoretical conceptualisation and measurement of FOR is 
only beginning to emerge, and limited interventions to reduce its impact have been 
tested. The current study aimed to explore the potential role of psychological 
flexibility, the underlying construct within Acceptance and Commitment Therapy 
(ACT), in mediating the relationship between severity of FOR and distress and 
quality of life (QOL) outcomes.  
Methods 
The study employed a cross-sectional questionnaire design. 75 post-treatment 
cancer survivors were recruited via cancer support centres, and completed a battery 
of assessment measures online or on paper. Relationships between predictor 
variables of FOR and psychological flexibility, and outcome variables of distress and 
QOL were explored, using multiple linear regression and Conditional Process 
Analysis.  
Results 
Findings showed that the severity of FOR was predictive of adjustment outcomes. 
While psychological flexibility as an overall construct did not significantly mediate 
these relationships, two processes within this framework, fusion to thoughts and 
valued living, were found to play a key role. Valued living had the strongest 
predictor of QOL and depression, while fusion with thoughts was most predictive 
of levels of anxiety.    
Conclusions 
Results point to the potential importance of understanding how individuals relate to 
their FOR in both in the identification of patients at risk of poorer adjustment, and 
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in guiding the development of interventions to reduce the impact of FOR. Further 
research using larger samples and longitudinal designs to replicate and expand this 
work is recommended. In particular, it will be important to consider the relative role 
of all of the processes conceptualised within psychological flexibility model.  
Implications for Cancer Survivors 
This study offers important insights into the key role of how individuals relate to 
FOR in mediating their impact, offering a potentially beneficial route for addressing 
currently unmet patient needs. 
 




















Cancer survivorship context 
With an ageing population and advances in screening and medical treatments, 
significantly more people are living with and beyond cancer. Survival rates have 
doubled in the last 40 years, with 50% of adults diagnosed with the disease now 
predicted to survive for at least 10 years [1]. Survival of course is not the only 
outcome of interest, and many survivors are troubled by late physical and 
psychological effects of treatment [2].  
Clinical anecdote and research evidence have suggested that there are distinct 
points in the trajectory where patients often experience psychological difficulties. 
Diagnosis, end of treatment, and diagnosis of recurrence have been identified as 
critical points of potential vulnerability for psychological distress [3-5]. It has been 
suggested that patients often function on a ‘basic physiological level’, putting 
emotions to one side in order to get through treatment [6]. Consequently, it is often 
only once treatment is completed that difficult emotions can come to the fore.  
Furthermore, during treatment, cancer patients are often told to expect symptoms to 
reduce or remit once treatment is completed, however this may not be the case for 
many individuals [7]. Stanton and colleagues [8] identified a number of unhelpful 
expectations or ‘myths’ that cancer patients may hold about completing treatment; 
such as ‘I should be celebrating’; ‘I should feel well’; ‘I should be the pre-cancer me’; 
and ‘I should not need support’. It has been suggested that psychological distress 
occurs when difficulties are experienced which are in contrast to patients own and 
family/friends’ expectations about returning to ‘normal’ [8].   
In recent years there has been increasing focus on the transition from active 
treatment into survivorship. This has been reflected in developments in 
international health policy, such as ‘Cancer Patient to Cancer Survivor: Lost in 
Transition’ in the USA [9], and more locally the ‘Transforming Care after Cancer 
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Treatment’ (TCAT) initiative [10]. Within the UK, current policy states that all 
patients should undergo psychological assessment at key points in their cancer 
pathway and have access to appropriate psychological support services where 
needed [11]. To successfully achieve this, it is crucial that research is carried out to 
establish which interventions are most effective for who and at which points in the 
cancer trajectory. In addition to improving patient care, there are important 
financial implications for delivering interventions at the point at which patients are 
about to leave routine hospital care, in terms of potential reductions in service use 
by preventing the escalation of psychological distress. 
Fear of cancer recurrence 
 
A small but increasing body of evidence has described common concerns reported 
during the transition to survivorship [12, 4, 8]. A common concern reported by 
patients at this point in their cancer journey is fear of recurrence (FOR), which can be 
defined as ‘Fear, worry, or concern relating to the possibility that cancer will come 
back or progress’ [13]. A degree of worry about the possibility of cancer returning 
following treatment is extremely common, and is an understandable, rational 
response to the life-threatening nature of the disease [14]. Indeed, a certain level of 
FOR is arguably helpful in motivating individuals to be vigilant for any signs of the 
cancer returning, in order that they receive medical intervention quickly. However, 
for some individuals, experiencing high levels of FOR has been associated with 
increased psychological morbidity, particularly in the months following completion 
of treatment [15], and has also been related to the exacerbation or development of 
psychiatric diagnoses such as Post Traumatic Stress Disorder and Generalised 
Anxiety Disorder [2]. In this context, it is unsurprising that FOR has also been 
shown to predict poor quality of life (QOL) [16]. It has also been shown to persist 
long after the completion of treatment, even when the risk of recurrence is 
statistically low [17]. Importantly, cancer survivors themselves have identified FOR 
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as the most common concern one year following treatment [12], and have indicated 
a desire for interventions to assist them in coping with uncertainty and FOR [6].  
A handful of qualitative studies have offered insights into the lived experience of 
FOR [18-20].  Patients in these studies described a process of constructing a ‘new 
normal’ after treatment as they managed an uncertain future and fears of the cancer 
returning. Some remarked on the loss of no longer attending hospital, which had 
previously provided a source of active coping, allowing access to medical 
reassurance and social support. Strategies patients reported for coping with these 
fears included attempting not to think about possible recurrence; trying to focus on 
the positive; and pushing distressing thoughts and memories of treatment to the 
back of their mind. However, for many patients these fears often intruded into 
consciousness as nightmares and flashbacks. While this research is based mainly on 
female breast and gynaecological cancer patients, limiting its generalizability to 
survivors of other cancers, it highlights FOR as a key concern faced by patients 
during the transition to survivorship, and attempts to avoid experiencing such fears 
as a common but often unhelpful coping strategy.  
There is a small body of evidence pointing to risk factors predicting which patients 
are most troubled by FOR. Three reviews have reported younger age; physical 
symptoms; low optimism; avoidant coping; poor QOL; and distress, anxiety and 
depression, as factors associated with higher FOR [14, 16, 21]. Weaker evidence has 
been reported for associations with disease and treatment variables, and 
inconsistent findings are reported for socio-demographic variables [14, 16, 21]. Prior 
mental health difficulties and existing psychiatric diagnoses are also risk factors [2]. 
Theoretical Formulation of FOR 
 
A number of existing psychological theories have been applied to the understanding 
of FOR, including the self-regulation model of illness [22]; Self-Regulatory Executive 
Functioning Model (S-REF) [23]; Uncertainty in Illness Theory [24]; Social-Cognitive 
Processing Model [25]; Family Based Model [26]; and Existential Psychotherapy 
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[27]. Though these models focus on distinct theoretical approaches to understanding 
the phenomenon, they share a number of overlapping components which have been 
helpfully summarised by Simonelli and colleagues [2]. Central processes are said to 
include the existence of internal (e.g. physical symptoms) and external (e.g. cancer 
related media) triggers, which are interpreted via cognitive emotional processes. 
These processes are themselves influenced by the social context and other 
contextual factors (e.g. age, additional life stress, past coping), and result in more or 
less adaptive coping. This process results in the experience of a range of 
psychological and behavioural responses, the more unhelpful of which include for 
example excessive checking for physical symptoms, worry and panic, and excess 
utilisation of medical services such as seeking frequent contact for reassurance.    
While evidence suggests a clear link between FOR and psychological distress, it 
remains unclear whether high levels of FOR lead to increased distress, or vice versa. 
Furthermore, while FOR is a common experience for cancer survivors, many do not 
develop psychological distress, raising questions about the processes mediating the 
relationship between FOR and negative outcomes. In order to develop effective 
interventions aimed at reducing the negative impact of FOR, the application of 
theoretical models to allow testing of specific hypothesised processes by which 
relationships between FOR and negative consequences exist is crucial.  
A handful of authors have begun to approach the topic in this way. In one study, 
individuals with elevated FOR and increased use of avoidance, denial, wishful 
thinking and reassurance seeking coping strategies were found to have the highest 
levels of psychological distress and functional impairments [28]. In another, holding 
back (from talking about cancer related concerns) and low self-esteem were found to 
significantly mediate the effect of FOR on depression [29]. Investigation of this type 
of mediation model offers exciting possibilities, not only for identifying patients at 
higher risk of experiencing poorer psychological adjustment, but also for identifying 
mediating mechanisms that could be formulated as treatment targets in the 
development of new interventions to facilitate adjustment.  
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Interventions Targeting FOR 
 
Whilst FOR is a common and potentially distressing issue for individuals 
transitioning to cancer survivorship, the development of interventions aimed at 
reducing its impact has been hindered by the fact that there is currently no agreed 
definition as to when it reaches problematic levels, and no gold-standard 
measurement tool [30]. Perhaps unsurprisingly then, evidence suggests that in 
many healthcare settings it is not being adequately addressed, with FOR having 
been reported as the most frequently endorsed unmet need among patients both 
immediately following treatment and 6 months later [31-32]. There have been a 
handful of studies testing interventions specifically aimed at reducing FOR in 
cancer patients. The first review of such interventions was recently published by 
Dawson and colleagues [33], and indicates that patient coaching/communication 
training, counselling, and mindfulness are potentially beneficial intervention 
approaches which require further exploration. 
Psychological Flexibility 
 
Due to the possibility that exists for all cancers to recur, FOR is an understandable 
and common experience. However, it is inherently threatening, and as such 
individuals may attempt to avoid or control these experiences. Such attempts are 
likely to be unsuccessful, in part due to exposure to potential triggers (e.g. physical 
symptoms; news about cancer; learning of the diagnosis of another). Therefore, 
acceptance-based models are intuitively appealing to conceptualising and 
developing interventions to address FOR.  
One such conceptual model which can be applied to understanding the impact of 
FOR on adjustment outcomes is that of psychological flexibility, the overarching 
framework within Acceptance and Commitment Therapy (ACT, said as one word) 
[34]. Within this framework, it is not aversive internal experiences themselves but 
persistent attempts to control and avoid them which can lead to or exacerbate 
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psychological distress, and reduce engagement in valued activities [35]. In contrast 
to the majority of psychotherapies, the goal of ACT is not symptom reduction, but 
to encourage patients to accept, let go of and become less dominated by unpleasant 
internal experiences, in order to live a more valued and meaningful life. It does not 
seek to examine the validity or ‘truth’ of experiences or attempt to modify thoughts, 
feelings and physical experiences directly, but focusses on changing how 
individuals relate to these experiences [36].  
ACT uses acceptance and mindfulness skills to increase psychological flexibility, 
defined as ‘the ability to contact the present moment more fully as a conscious human 
being, and to change or persist in behaviour when doing so serves valued ends’ [37, p.5]. Six 
overlapping core processes are conceptualised within the psychological flexibility 
model – acceptance, cognitive defusion, being present, self as context, values, and 
committed action, with psychological inflexibility being the converse of these 
processes [36]. Within this ‘hexaflex’ of positive psychological processes, two main 
overlapping groupings are identified as mindfulness and acceptance processes, and 
commitment and behaviour change processes [36]. 
There is growing evidence that psychological flexibility mediates the relationship 
between negative symptom experiences and outcomes in chronic pain [38-39]; 
Irritable Bowel Syndrome [40]; and tinnitus [41], to name but a few. The recent work 
of Garland and colleagues [42] has further provided insight into the process by 
which higher levels of dispositional mindfulness links via positive reappraisal, 
greater attention to positive information, and increased savouring, to outcomes of 
higher QOL and lower emotional distress.  
A few authors have begun to explore the relevance of the model in understanding 
adjustment to cancer. For example, Ciarrochi and colleagues [43] reported that 
success in living according to values was associated with reduced distress and 
increased wellbeing in a sample of mixed cancer patients, and Gillanders et al. [44], 
reported that psychological flexibility was predictive of distress even after variance 
associated with known predictors (appraisals and avoidance coping) was accounted 
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for. Furthermore, a handful of recent intervention studies have provided 
preliminary evidence for the effectiveness of acceptance-based interventions with 
cancer patients [45-47]. To date, there are only two known studies which have 
investigated the effectiveness of acceptance-based interventions for addressing FOR 
in cancer survivors [48-49]. Preliminary results from these studies are promising, 
suggesting that the intervention leads to improvements in fear of cancer recurrence 
and related outcomes at this point in the cancer journey. 
Aims of Current Study 
 
Applying a psychological flexibility model to understanding the impact of FOR 
could have useful clinical implications. Firstly, it could potentially enable more 
effective screening for those who are likely to be at increased risk of distress and 
reduced QOL as a result of FOR. Secondly, it could inform the development of a 
brief intervention to increase psychological flexibility as a way of reducing the 
impact of FOR. This is particularly important given that health professionals have 
indicated a desire for increased knowledge about effective strategies for managing 
FOR [50]. The current study takes an important first step in this process, by 
exploring the role of psychological flexibility in influencing the relationship between 
the experience of fear of cancer recurrence and poorer adjustment in terms of 
increased distress and reduced QOL. It was hypothesised that when individuals 
relate to FOR in a psychologically inflexible way, they may engage less in value 
driven activity, and experience increased distress and reduced QOL. Conversely, 
individuals who relate to FOR with psychological flexibility and continue to engage 
in valued activity might be expected to be less negatively impacted.  
As the field of ACT research is in its relative infancy, there is currently no agreed 
‘gold standard’ method of measuring psychological flexibility. A secondary study 
aim was therefore to compare the performance of an overall measure of 
psychological flexibility versus individual measurement of the component parts of 
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The study employed a cross-sectional questionnaire design, in which self-selected 
cancer survivors were recruited to complete a battery of validated self-report 
questionnaires measures on one occasion. Within the UK, there is large variability 
within models of hospital follow up post cancer treatment, dependent on cancer 
type [51]. The population of interest was therefore a potentially hard-to-reach 
group. To address this, a mixed paper-based and online data collection approach 
was used, in conjunction with recruitment via third sector cancer support services. 
Internet based research is a relatively new tool within psychological research and 
offers a number of potential benefits including: collection of a large data set from 
range of demographic groups; elimination of potential researcher bias in 
recruitment and data collection; and facilitation of enhanced self-disclosure from 
participants [52]. There is evidence to support the validity and reliability of 
psychological measures administered online versus. using pen and paper [53], 
including ACT specific measures [54].    
Procedure 
Ethical approval for the study was granted by the University of Edinburgh School of 
Health in Social Science Research Ethics Committee, and the South East Scotland 
Research Ethics Committee (REC Reference: 15/SS/0116). Potential participants were 
informed about the study through adverts posted online and within local cancer 
support organisations, and information disseminated via relevant social media. 
Interested individuals were invited to contact the researcher if they wished further 
information, or to request a paper copy of the questionnaire pack. Questionnaire 
packs were also made available within local cancer support centres. Those wishing 
to complete the study online were invited to click on the web-link to proceed to the 
study page. All participants were informed of the study’s aims, methods, likely 
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risks, freedom to withdraw or decline at any time, storage, retention and processing 
of data. Having received this information, choosing to take part by completing the 
eligibility form and questionnaire pack was taken to imply consent. Participants 
were made aware that as all answers were non-identifiable they could not be 
deleted once provided. 
Sample 
Inclusion and Exclusion Criteria 
Individuals eligible to take part in the study were those who were aged 18 or over; 
able to read in English; had received a diagnosis of any cancer; had completed 
curative cancer treatment, including surgery, chemotherapy, radiotherapy (or any 
combination of these treatments); and had no evidence of current cancer. Those 
receiving ongoing hormonal or Herceptin treatments were also eligible, consistent 
with the majority of similar research studies in the field of cancer survivorship [e.g. 
55]. All cancer types were included in the study due to insufficient evidence to 
suggest substantial differences in prevalence rates of psychological distress and 
FOR between different cancers [14].  
Changes to Planned Study Protocol 
The original study protocol defined eligibility as above, with the additional 
requirements that individuals were resident within the UK, and had completed 
their cancer treatment within the preceding 24 months. However, in the initial 
months of recruitment, it became apparent that these additional criteria may be too 
restrictive, and be preventing interested individuals who felt the research was 
relevant to them from taking part. Therefore, these criteria were removed following 
approval from the research ethics committee, and recruitment continued with the 
more inclusive criteria. The relative numbers of participants recruited prior to and 
following the widening of criteria was 32 and 43 respectively.  
Measures 
Participants completed eight self-report measures relating to the variables of 
interest, on one occasion. The format did not differ between the paper 
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questionnaires and those completed online.  Demographic information on 
participants’ gender, age, cancer type, year and month of diagnosis, treatments 
received, month and year of treatment completion, and any previous cancer 
diagnoses and treatment was also collected.   
Fear of Recurrence  
The Fear of Cancer Recurrence Inventory (FCRI) short form [56] is a 9 item self-
report questionnaire measuring the severity of FOR experienced. Higher scores on 
the measure indicate increased severity of FOR. It was developed by the original 
authors from their 42-item original measure. Initial validation indicated that the 9-
item severity subscale has been shown to be highly correlated with the total 
measure score (r=.84). Internal consistency for the current study was good, with a 
Cronbach’s alpha of 0.86. The authors suggest the use of this subscale as a short 
form of the measures for screening purposes, and to date it has been the most 
widely used brief screening tool for FOR [57].  
Psychological Flexibility – Overall Measure 
The Acceptance and Action Questionnaire II (AAQII) [58] is a seven-item 
questionnaire measuring the overall construct of psychological flexibility. Items are 
rated on a 7-point Likert scale from 1=never true, to 7=always true, giving a total 
score between 7 and 49. Higher scores on the measure indicate greater levels of 
psychological inflexibility. It has been shown to have good test-retest reliability 
(r=0.81 at 3 months, r=0.79 at 12 months) and discriminant validity, and in the 
current study had very good internal consistency of 0.94. It is currently the most 
widely used general measure of psychological inflexibility, and was selected for the 
study based on its brevity and superior internal consistency to the 9-item version.  
Psychological Flexibility – Individual Process Measures 
The 15 item Brief Multidimensional Experiential Avoidance Questionnaire 
(BMEAQ) [59] contains 15 items measuring avoidance of: pain; uneasiness; effort; 
upset; unpleasantness; discomfort; emotions; painful emotions; feelings; bad 
feelings; upsetting feelings; fear/anxiety; unpleasant memories; and doubts. Each 
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item is scored on a 6-point likert scale from strongly disagree (1) to strongly agree 
(6), with item 6 being reversed. The item scores are then summed, with higher total 
scores indicating higher levels of avoidance.  The BMEAQ has been validated using 
a variety of samples, and shown to have good construct validity, and strong 
convergence with the 6 dimensions of experiential avoidance measured with the 
original 62 item MEAQ [59]. In the current study, the internal consistency of the 
measure was good, with a Cronbach’s Alpha of 0.88.   
The Cognitive Fusion Questionnaire (CFQ) [54] is a 7-item questionnaire measuring 
the relationship individuals have with their cognitions on a continuum of fused 
(entangled with, believed, dominated by) to defused (able to view from detached 
perspective as mental events not necessarily to be acted on) [54]. The measure has 
been validated with a range of populations, including cancer and survivor 
populations. It has been shown to have good test-retest reliability and adequate 
divergent validity [54]. In the current study, the internal consistency of the measure 
was excellent, at 0.94. 
The 16 item Engaged Living Scale (ELS) was developed by Trompetter et al., [60] to 
measure valued living and committed action. The self-report questionnaire contains 
10 items measuring valued living and 6 items measuring life fulfilment, all 
measured on a 5-point Likert scale from ‘completely disagree’ to ‘completely agree’. 
Higher scores indicate higher levels of value based living. Originally developed in 
Dutch, it has been reliably translated into English. To date, the questionnaire has 
been validated with non-clinical and chronic pain samples, and demonstrated good 
construct validity (moderate to high correlations with AAQ-II scores) [60]. In the 
current study, the measure had an excellent level of internal consistency, with a 
Cronbach’s Alpha of 0.92.     
The Mindful Attention Awareness Scale (MAAS) [61] is a 15 item questionnaire 
measuring dispositional mindfulness, or the extent to which an individual is 
attentive to and aware of the present moment. The items assess the frequency with 
which an individual is mindful in a range of general and specific situations. Each 
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item is rated on a Likert scale between 1 (almost always) and 6 (almost never). The 
mean of the total item score is then calculated to provide an overall measure of 
mindfulness, with higher scores reflecting greater mindfulness.   The measure has 
been validated with student and general adult samples [61], and shown to have 
good convergent and discriminant validity. It has been further validated with a 
modest sample of cancer outpatients [62], and was suggested to be an appropriate 
measure of mindfulness within cancer populations. In the current study, the 
measure had good level of internal consistency, with a Cronbach’s Alpha of 0.90.  
Psychological Distress  
The Hospital Anxiety and Depression Scale (HADS) [63] is a 14-item questionnaire 
developed to measure symptoms of anxiety and depression within populations with 
physical illness. It contains 7 items for anxiety and 7 for depression, each scored 
from 0 to 3, with higher scores indicating increased levels of distress. The HADS is 
widely used in research and clinical practice, and has been shown to have good 
concurrent validity [64]. In the current study, the Cronbach’s alpha of the measure 
was 0.79 for the anxiety subscale, and 0.80 for the depression subscale, indicating 
good internal consistency.  
Quality of Life 
The Functional Assessment of Cancer Therapy – General (FACT-G) questionnaire 
[65] is the most widely used self-report measure of QOL in cancer populations. It 
contains four subscales of: physical well-being (7 items); social/family well-being (7 
items); emotional well-being (6 items); and functional wellbeing (7 items). All items 
are measured on a 5-point scale from 0 (not at all) to 4 (very much), and higher 
scores indicate higher perceived QOL. The questionnaire has been validated with 
mixed cancer patients and long-term survivors. It has been shown to have good 
convergent and discriminant validity, and good test-retest reliability (correlations 
coefficients between .82 and .92) [65]. Only the physical, social/family, and 
functional well-being subscales were utilised in this study, as the emotional 
wellbeing subscale contains items which overlap with distress and FOR constructs 
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(e.g. I worry that my condition will get worse). The developers have suggested that 
individual subscales can be used as appropriate, and that the measure is suitable for 
computer based administration [66]. The Cronbach’s Alpha of the subscales in the 
current study ranged from 0.75 to 0.86, indicating acceptable to good internal 
consistency of the measure.   
Statistical Analyses 
A Priori Sample Size Calculation 
An a priori sample size calculation estimated that a minimum sample size of 146 
participants was required, based on a power level of 0.8 and significance level of 
0.05. At the time of completion, there have been no previous studies investigating 
the relationship between FOR, psychological flexibility, distress and QOL, therefore 
the estimate was based on detecting a medium effect size or larger. The power 
calculation was completed using G*POWER 3 [67].  
Preliminary Analyses 
All data analyses were performed using SPSS 23 (IBM SPSS 23). Preliminary steps 
involved screening of the data to identify missing data and outliers, and establish 
that the data met necessary assumptions for parametric statistical testing.  
Exploration of the frequency and potential patterns of missing data revealed a very 
small total amount of missing values from the dataset (0.9%). Across cases, there 
was one case which was identified as having a proportionately larger amount of 
missing data (14%). However, as the case contain less than 20% missing data it was 
retained in order to preserve power. Item level analysis across the sample revealed 
that the two items with most missing data were items 6 and 7 on the FACT-G 
social/family wellbeing subscale (8.3% and 18.1% respectively). These items related 
to the quality of main supportive relationships, and satisfaction with sex life. It 
could be hypothesised that these items contained more missing data because of 
perceived non-applicability, as well as potential discomfort in answering questions 
of this nature, and possibly therefore be missing not at random (MNAR), that is, to 
be missing based in a pattern relating to a variable which had not been recorded. It 
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was also identified that there were three other items with >5% of missing data, all 
from the MAAS (q13, q14, & q15). Examination of completed paper questionnaire 
responses revealed that due to formatting, these three items appeared over the page 
from the scoring instructions, and therefore are likely to have been missing by 
design. These items could therefore be assumed to be missing completely at random 
(MCAR).  To aid decision making around the approach taken to deal with missing 
data, Little’s Missing Completely at Random (LCAR) test [68] was performed and 
was not found to be significant, indicating that overall, missing values were likely to 
be missing in a random pattern. 
Based on these findings, an expectation maximisation approach was selected to 
impute missing data. This method of imputation predicts most likely values based 
on the data provided [69], and has been suggested to be the most robust way of 
dealing with missing data where there are small amounts of missing data which are 
missing at random [70]. This approach was selected in place of a deletion method 
which may have introduced bias in the case that the values were not missing 
completely at random, as well as reducing the power of the analysis.      
Participant demographics were explored using descriptive statistics. All variables 
were assessed for potential outliers, based on a calculation of the differences 
between the upper and lower quartiles multiplied by 3 [71]. Visual examination of 
histograms and calculation of z scores for skewness and kurtosis revealed that all 
variables were normally distributed. Data were therefore found to meet basic 
assumptions required for the use of parametric statistical tests [72]. 
Further tests to establish that the data met assumptions for regression analyses were 
carried out. Examination of partial regression plots and studentized residuals 
against predicted values confirmed the assumptions of linearity, homoscedasticity 
and normality of residuals. There was no evidence of multicollinearity, as indicated 
by all tolerance values being greater than 0.2. The assumption of independent errors 
was met, as assessed by a Durbin-Watson statistic close to 2 in all cases, and Cooks 





Recruitment to the study took place between September 2015 and June 2017. During 
that period, there were a total of 3,511 views of the study information homepage. Of 
the 92 individuals who opted to take part in the online questionnaire, 6 (7%) were 
screened out through the eligibility questions; 27 (29%) ceased participation during 
the eligibility screening and demographic information questions; and 8 (9%) ceased 
participation during completion of the outcome measure questions, leaving an 
incomplete dataset. This left a total of 51 complete online participant responses for 
analysis. Of the paper questionnaire packs returned (n=27), 2 were screened out 
through the eligibility questions, and 1 was ruled to be ineligible through free text 
comments about treatment outcome, leaving 24 complete paper responses for 
analysis. This gave a total combined final sample of 75. 
The majority of participants were female (92.0%), with a mean age of 51.9 years 
(range 19-88). Most participants had completed treatment for breast cancer (69.3%), 
while the rest of the sample was made up of mixed cancer survivors. Although 
breast cancer remains the most common cancer within the UK, accounting for 15% 
of all cases [1], it remains over-represented within the sample. Conversely, lung and 
prostate cancer were under-represented within the sample, with only one lung 
cancer and no prostate cancer patients taking part, despite these cancers each 
accounting for 13% of all cases [1].    
 Average mean time since diagnosis was 3.5 years (range 0 – 28 years), and the mean 
average time since treatment completion was 2.2 years (range 0 – 9), with 71.2% of 
the sample having completed treated within the past 2 years. Most patients had 
undergone surgery (90.7%); with a majority having also undergone chemotherapy 
treatment (69.3%) and/or radiotherapy treatment (70.7%). Around half of the sample 
(48.0%) were receiving ongoing adjuvant hormonal therapy at the time of 
participation. 
Table 1b. Descriptive statistics for key participant characteristics 
110 
 
Characteristic Mean (SD, %) 





















Time since diagnosis 







More than 5 years 
Not known 
 












































Time since treatment completion 












































*Other included lung, melanoma, gynaecological, thyroid, kidney, and testicular 
cancers. 
 
Levels of FOR, Distress and QOL  
Table 2b provides a summary of the mean predictor and outcome variable scores 
sample. Comparisons were made with general population and cancer normative 
scores (from mixed treatment status patients), where available. The mean FOR score 
for the sample was 20.03, which is considerably higher than the cut-off of 13, 
suggested to indicate clinical levels [57]. Comparison with total QOL (FACT-G) 
norms was not possible as, for the reasons described earlier, the emotional 
wellbeing subscale was not used in the current study. However, comparison of the 
three subscale scores which were used with both general population [73] and cancer 
patient [74] samples indicates that current sample had generally poorer QOL than 
both groups, except for the physical wellbeing subscale, where scores were lower 
than general population norms but higher than other cancer samples. This suggests 
the current sample were generally less troubled by difficulties with their current 
physical health than the overall general cancer population, which is in keeping with 
the fact that the sample were all post treatment cancer patients who were a few 
years from the end of treatment. In line with recommendations [75] median distress 
(HADS) scores were compared with normative median values rather than 
comparing proportions of participants meeting cut offs for clinical levels of distress. 
Comparison with data from a UK general population sample indicates that HADS 
scores for this sample were higher than normative levels for both anxiety (8.63 vs. 
6.14) and depression (5.63 vs. 3.68) [76], and slightly higher than cancer population 












Mean score SD Range 
Predictor Variables 
 
FCRI-Severity 0 – 36 20.03 6.58 2 – 34  
BEAQ 15 – 90 50.66 14.38 16 – 80 
ELS Total 0 – 80   55.80 13.35 19 – 80  
MAAS 15 – 90 56.05 13.57 20 – 88  
CFQ 7 – 49 26.96 8.72 7 – 45  
AAQ-II 7 – 49 23.02 9.36 7 – 42  
Outcome Variables 






0 - 21 
0 - 21 










0 – 17  
0 – 17  
0 – 31 
Note: FCRI = Fears of Cancer Recurrence Inventory, BEAQ= Brief Experiential Avoidance 
Questionnaire, ELS= Engaged Living Scale, MAAS= Mindful Awareness and Attention Scale; 
CFQ= Cognitive Fusion Questionnaire, AAQ-II= Acceptance and Action questionnaire II; 
FACT-G= Functional Assessment of Cancer Therapy; HADS= Hospital Anxiety and 
Depression Scale  
 
Covariate Analyses 
Analysis of variance (ANOVA) was performed between categorical demographic 
and clinical variables of gender and treatments received (i.e. surgery; chemotherapy; 
radiotherapy; hormonal therapy; and Herceptin), to identify potential confounding 
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variables. None were significant (p<0.05), except for Herceptin, whereby FOR scores 
were significantly higher in those who had received Herceptin treatment relative to 
those who had not (F=7.15, p<.01). Correlation analyses were also run between 
continuous variables of age, time since diagnosis, and time since treatment 
completion. Both time since diagnosis and time since treatment completion were 
significantly negatively correlated with FCRI total scores, in that as time since 
diagnosis and treatment completion increased FCRI scores reduced (r= -.448, p<.01; 
r=-.460, p<.01). A positive correlation was also found between age and mindfulness, 
with mindfulness scores increasing with increasing age (r=.360, p<0.01). Age, time 
since diagnosis, time since treatment, completion method and Herceptin treatment 
were therefore included as covariates within the planned multiple regression and 
mediation analyses. However, in both cases entering the covariates into the model 
did not significantly change the findings, therefore all analyses’ results presented 
are without the inclusion of covariates in order to preserve power.   
 
Correlation Analyses 
Bivariate Pearson’s correlations were initially performed to explore direct 
associations between all variables. Results are presented in table 3b. Generally 
strong correlations were found in directions consistent with existing research and 
theory. As all outcome variables were significantly correlated with at least one of 








Table 3b. Correlation matrix presenting correlations between predictor and outcome 
variables 
 1 2 3 4 5 6 7 8 9 10 
1           
2 .364 **          
3 -.247* -.542**         
4 -.446** -.550** .462**        
5 .450** .595** -.653** -.421**       
6 .416** .495** -.490** -.420** .819**      
7 -.265* -.161 .396** .156 -.366** -.344**     
8 .517** .477** -.500** -.529** .679** .661** -.495**    
9 .310** .425** -.500** -.371** .449** .403** -.664** .611**   
10 .461** .502** -.557** -.502** .629** .593** -.645** .898** .897**  
** correlation significant at the 0.01 level (2-tailed), * correlation significant at the 0.05 level 
(2-tailed) 
Note: 1= Fears of Cancer Recurrence Inventory (FCRI), 2= Brief Multidimensional 
Experiential Avoidance Questionnaire (BMEAQ), 3= Engaged Living Scale (ELS), 4= Mindful 
Attention Awareness Scale (MAAS), 5= Action and Acceptance Questionnaire II (AAQII), 6= 
Cognitive Fusion Questionnaire (CFQ), 7= Functional Assessment of Cancer Therapy – 
General (total) (FACT-G), 8= Hospital Anxiety and Depression Scale – Anxiety subscale 
(HADS-A), 9= Hospital Anxiety and Depression Scale – Depression subscale (HADS-D), 10= 






Incremental Validity Assessment of Measures of Psychological 
Flexibility 
In order to decide on the most appropriate measure of psychological flexibility to 
use, i.e. the overall measure (AAQ II) or the individual process measures 
(experiential avoidance, mindfulness, cognitive fusion and valued living), 
hierarchical multiple linear regression analyses were conducted to allow exploration 
of the incremental predictive validity of each approach over the other [78]. As there 
is currently no agreed consensus on any one ‘gold standard’ measure of 
psychological flexibility, the hierarchical regressions were run twice, first 
considering the incremental predictive efficacy of the AAQ over and above the 
variance explained by the individual process measures, and then vice versa. A 
forced method of entry was used, in which step one involved entering the four 
process measures (experiential avoidance; cognitive fusion; mindfulness and valued 
living), followed by the overall measure (AAQ II) at step 2, and vice versa. The 
change in predictive ability of the model between each step was then examined.  
For the first regression predicting QOL (QOL), the overall model including all five 
predictors accounted for 13.3% of the variance in QOL scores (adjusted R2 = .133) 
and was statistically significant (F (5,69) = 3.264, p<0.05). Addition of the overall 
psychological flexibility measure into the model increased the predictive ability of 
QOL only by a very small amount of 0.3% (R2 change=0.003), which was not a 
statistically significant change, p=.606 ns. The introduction of the individual process 
measures at step 2 increased the variance predicted by a larger amount (6.2%), 
although this change was also not statistically significant (p=.271 ns).  
For the regression predicting anxiety, the model including all five predictors 
accounted for 54.6% of the variance in HADS anxiety scores (Adjusted R2=.546), and 
was highly significant F(5,69)=18.814, p<.001. The addition of the overall 
psychological flexibility measure into the model increased the amount of variance 
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explained by a small amount of 3.2% (R2 change = .032), which was a statistically 
significant increase (p<.05). When the analysis was repeated other way round 
however, the addition of the individual process measures to the single measure to 
increase the predicted variance by an additional 10.9%, which was a statistically 
significant increase (p<.01). 
For the model predicting depression, the overall model including all five predictors 
accounted for 26.4% (Adjusted R2 =.264) of the variance in HADS depression scores, 
and was highly significant (F (5,69) = 6.304, p<.001). In this case the addition of the 
overall psychological flexibility measure into the model did not increase the 
predictive efficacy of the model at all (R2 change =0.00, p>0.05), however results from 
analyses with the individual measures introduced at the second step showed that 
they increased the predicted variance by 11.4%, and that this was a statistically 
significant change (p<.05). 
Taken together, these results indicate that although the incremental increase in 
predictive ability between the two measurement approaches was more prominent 
for the measurement of anxiety and depression outcomes than for QOL, the overall 
performance of the measures indicate that use of the individual process measures of 
psychological flexibility offers increased predictive power over and above what can 
be predicted using the AAQ-II. The remainder of the analyses were therefore 
performed using the four individual measures capturing the construct of 
psychological flexibility.  
Prediction of Anxiety, Depression and QOL 
The next stage in the analyses involved conducting a series of single step multiple 
regressions to examine the relative predictive ability of the independent variables of 
FOR and psychological flexibility on the outcomes of QOL and distress. 
The first model assessed the predictive power of the five independent variables on 
overall QOL, as measured by the total of the three FACT-G subscale scores (physical 
wellbeing, social-family wellbeing, and functional well-being). When entered into 
the model, the five predictors accounted for 17.4% of the variance in overall QOL 
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(adjusted R2=.174), and the model was statistically significant (F (5,69)4.117, p<.01). 
Examination of the relative predictive power of variables revealed that only valued 
living significantly predicted the total QOL score (𝛽𝛽= .386, p<.05). 
The second set of regression analyses testing the five predictor variables on anxiety, 
showed that overall the model predicted 53.4% of the variance in HADS anxiety 
scores (adjusted R2=.534), and the model was highly significant (F (5,69) = 17.944, 
p<..0001). Looking at the relative predictive value of individual variables, both FOR 
and cognitive fusion significantly predicted anxiety (FOR  𝛽𝛽 =  .224,𝑝𝑝 = .019; CF 
𝛽𝛽 =  .412,𝑝𝑝 < .0001). 
For the model of depression, the five predictors together accounted for 26.6% of the 
variance in HADS depression scores, which was highly significant (F(5,69)= 6.356, 
p=<.001). Of the individual predictor variables, only valued living significantly 














Table 4b. Results of linear regression analyses for the prediction of QOL, anxiety and 
depression 
 𝜷𝜷 T P Adj. R2 F (5,69) P 
Dependent variable: Overall QOL (Total FACT-G score) 
FOR -.192 -1.547 .126    
Experiential 
Avoidance 
.158 1.116 .268    
Valued Living  .386 2.864 .006    
Mindfulness -.103 -.752 .455    
Cognitive 
Fusion 
-.197 -1.476 .144    
Model 
summary 
   .174 4.117 .002 
Dependent Variable: Anxiety (HADS-Anxiety score) 
FOR .224 2.411 .019    
Experiential 
Avoidance 
.008 0.073 .942    
Valued Living -.156 -1.540 .128    
Mindfulness -.180 -1.748 .085    
Cognitive 
Fusion 
.412 4.109 .000    
Model 
Summary 
   .534 17.944 .000 
Dependent Variable: Depression (HADS-Depression score) 
FOR .113 .967 .337    
Experiential 
Avoidance 
.120 .897 .373    
Valued Living -.325 -2.561 .013    
Mindfulness -.058 -.445 .657    
Cognitive 
Fusion 
.113 .896 .373    
Model 
Summary 








Taken together, the results of multiple regression analyses indicated that FOR and 
psychological flexibility significantly predicted both QOL and distress within the 
sample. Of the psychological flexibility process measures, only the processes of 
cognitive fusion and valued living emerged as significant predictors of distress and 
QOL. To test the theoretically driven hypothesis that the relationship between FOR 
and both QOL and distress would be mediated by these psychological flexibility 
processes, Conditional Process Analysis [79] was performed. The advantage of this 
method is that it allows identification of the relative contributions of direct and 
indirect effect pathways on outcomes using more complex modelling techniques 
than is possible with standard regression analyses, and has increased power to 
detect indirect effects than other mediation methods [79]. Bootstrapped confidence 
intervals were calculated, whereby repeated ‘bootstrap’ samples were taken (in this 
case 10,000 times) to provide a more robust estimate of sample parameters [72].  
Where the 95% confidence intervals do not include zero, the path effect is 
considered to be significant at the p<.05 level.   
 
Mediating Role of Psychological Flexibility on the Relationship between 
FOR and QOL  
Separate mediation models were testing for each of the three outcomes of interest; 
QOL, anxiety and depression.  
The model predicting QOL explained 23% of the variance in QOL scores (R2=.23, F 
(5,69) = 4.12, p<.001). FOR did not directly predict QOL, however the total effect of 
the model including all the mediating variables was a significant predictor. Looking 
at the relative indirect effects of the individual process measures, the path is 
mediated through valued living, whereby higher FOR leads to reduced QOL via 
reduced valued living. None of the other process measures significantly mediated 




















    
 
Numbers on the paths represent standardised 𝛽𝛽 coefficients * p<.05, ** p<.01 
Significant paths shown (            = direct path,             = indirect paths), * p<.05, ** p<.01 
 
 Bootstrapped Confidence Intervals 
Path LL UL 
Direct effect of FOR on QOL   -.83 .10 
Total indirect effects -.92 -.08 
FOR to experiential avoidance to QOL -.03 .18 
FOR to engaged living to QOL -.23 -.01 
FOR to mindfulness to QOL -.05 .19 
FOR to cognitive fusion to QOL -.27 .02 
Total model: R2= .23, p=.01 f2=4.12 
Note: LL= Lower limit of Confidence, UL= Upper limit of confidence 







For anxiety, 57% of the variance in anxiety scores was predicted by the model 
(R2=.57, F (5, 69) = 17.94, p<.001). Within this model, there was a significant indirect 
effect of all mediating variables on FOR. While this effect attenuated the direct 
predicting power of FOR on anxiety the direct effect remained significant. Looking 
at individual process measures, only cognitive fusion had a significant indirect 
effect, suggesting higher cognitive fusion to partially mediate the relationship 
between higher FOR predicting higher anxiety scores.  
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Numbers on paths represent standardised 𝛽𝛽 coefficients * p<.05, ** p<.01 
Significant paths shown (            = direct path,             = indirect paths), * p<.05, ** p<.01 
 
 
 Bootstrapped Confidence Intervals 
Path LL UL 
Direct effect of FOR on Anxiety   .02 .24 
Total indirect effects .11 .46 
FOR to experiential avoidance to anxiety -.08 .08 
FOR to engaged living to anxiety -.01 .14 
FOR to mindfulness to anxiety .00 .21 
FOR to cognitive fusion to anxiety .05 .35 
Total model: R2= .27 , p= .00  f2= 26.68 
Note: LL= Lower limit of Confidence, UL= Upper limit of confidence 







The model for depression predicted 32% of variance in depression scores (R2=.32, F 
(5,69) = 6.36, p<.00). The total combined indirect effect of all mediators on depression 
was significant, and when added to the model the direct effect of depression became 
non-significant. This indicates that together, the psychological flexibility process 
variables mediate the relationship between FOR and depression. However, when 
considering the mediating variables in turn, none individually significantly 
mediated between FOR and depression. It was considered possible that this finding 
may have been due to the different scoring systems employed between the 
mediating variable measures, with some measured in the direction of higher scores 
meaning better outcomes, and some higher scores meaning poorer outcomes. To test 
the hypothesis that this may have had a suppression impact on the mediation 
analysis, it was re-run having transformed the mediating variable total scores so 
that they all measured in the direction of higher scores equalling better outcomes. 
However, the results of this analysis were the same, and therefore only original 






























    
                                                                              
Numbers on the paths represent standardised 𝛽𝛽 coefficients * p<.05, ** p<.01 
Significant paths shown (            = direct path,             = indirect paths), * p<.05, ** p<.01 
 
 Bootstrapped Confidence Intervals 
Path LL UL 
Direct effect of FOR on Depression -.07 .20 
Total indirect effects .02 .40 
FOR to experiential avoidance to depression -.05 .16 
FOR to engaged living to depression .00 .22 
FOR to mindfulness to depression -.09 .16 
FOR to cognitive fusion to depression -.04 .20 
Total model: R2= .10, p= .01, f2= 7.74 













Findings from this study suggest that fear of cancer recurrence plays an important 
role in predicting adjustment outcomes for cancer survivors. Consistent with 
findings from Humphris and colleagues [15], current data suggest a correlation 
between FOR and levels of psychological distress. However, in contrast to previous 
research [16], no direct relationship between FOR and QOL was found. 
The current study also builds on existing literature by providing unique insights 
into the role of psychological flexibility in mediating the impact of experiencing fear 
of cancer recurrence on post treatment cancer survivors. Findings suggest that as an 
overall construct, psychological flexibility does not appear to mediate the 
relationship between fears of recurrence and distress and quality of life. However, 
two of the processes measured within the overall concept of psychological 
flexibility, valued living and cognitive fusion, did emerge as significant mediators.  
This suggests that increased fear about cancer recurrence, may impact negatively on 
individuals in part via its effect on increased entanglement with thoughts and 
decreased engagement in valued activity. Interestingly, levels of mindfulness and 
experiential avoidance were not supported by the current data as significant 
mediators of the impact of fear of cancer recurrence. These results are contrary to 
existing evidence pointing to the role of psychological flexibility in predicting 
outcomes [44,80], as well as to qualitative evidence suggesting increased levels of 
acceptance-based coping (as opposed to avoidance based coping) within breast 
cancer survivors predicted less distress and depression [81]. More broadly, findings 
also appear to be at odds with previous mediation studies reporting avoidance to be 
key in influencing the effect of FOR on cancer patients [82-83].  
While the results of the current study do not support the role of psychological 
flexibility as an overall construct in understanding the nature and impact of FOR, 
they do suggest that the way in which an individual relates to their experiences of 
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fear is a key pathway through which these experiences negatively impact on 
wellbeing. This provides important information in terms of offering an alternative 
to the traditional CBT route of focussing on challenging the content such thoughts. 
The implications of this are twofold. Firstly, it suggests the potential use of 
screening for existing levels of cognitive fusion and value based living as a way of 
identifying those cancer survivors for whom high levels of FOR are more likely to 
lead to negative outcomes. Secondly, it highlights the potential for interventions 
aimed at helping individuals be less fused to and dominated by their thoughts, as 
well as helping them to live more successfully in accordance with their values, as a 
potential target for ameliorating adjustment outcomes in post treatment survivors. 
Given that FOR is to a degree a rational and normative response to cancer, focussing 
on these processes rather than challenging the content of such thoughts offers a 
target for intervention which is potentially more amenable to change. 
Using more complex mediation modelling analyses, the current results provide 
useful insights into particular aspects of psychological flexibility which appear to 
play a key role in influencing outcomes.  Findings suggest that living in accordance 
with one’s values is the most important predictor of both QOL and depression, 
while the degree to which an individual is fused to their thoughts as well as the 
severity of their fears about the possibilities their cancer will recur appear to have 
the most significant influence on levels of anxiety. These findings are in line with 
previous evidence from Ciarrochi and colleagues [43], where valued living was 
significantly related to reduced distress and improved wellbeing in a cancer patient 
sample. They also corroborate the results of a recent study by Gillanders et al. [44], 
where cognitive fusion was found to be the strongest predictor of anxiety in a 
sample of mixed cancer patients. The failure to find support for the overall model of 
psychological flexibility, while supporting the mediating role of two individual 
processes measured within the overall concept of psychological flexibility raises 
interesting questions about the conceptualisation and measurement of the concept 
as a whole. Further research to replicate and extend these findings would therefore 
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be useful, to allow firmer conclusions to be drawn about the utility of the 
psychological flexibility model as a potential treatment target for this population.  
In relation to the secondary research aim of exploring the incremental predictive 
validity of individual process measures versus an overall psychological flexibility 
measure, findings indicate that measurement of the construct at the individual 
process measures level allows for increased power to predict distress outcomes. The 
measures performed more similarly in predicting QOL, however the individual 
measures were still marginally better. The issue of the specificity of measures of 
ACT based constructs is an important one. Psychological flexibility is 
conceptualised as the overarching construct underlying six core processes of 
acceptance, mindfulness, cognitive defusion, self as context, values and committed 
action [34]. It is therefore understandable that the process measures have been 
found to correlate highly with each other. The AAQ [58] is a valid and popular 
measure which provides a robust overall assessment of psychological flexibility, 
and is therefore particularly useful when research is interested in initial explorations 
around the associations of psychological flexibility with different outcome variables 
or within new samples. However, once such associations have been identified, it 
could be argued that the use of process level measurement allows for the 
identification of individual elements of psychological flexibility emerging as key 
predictors. This could have important implications for the development of 
interventions which particularly target or focus on those elements found to account 
for the greatest variance in outcomes. Indeed, as was the case in the current study, 
measurement of individual processes rather at the level of an overarching construct 
allows a more sensitive level of analysis which could potentially reduce the chances 
of both Type 1 and Type 2 errors being made.  
Findings from the current study identified a number of potentially confounding 
variables. Firstly, a significant positive relationship between levels of mindfulness 
and age were observed. This is in line with findings from previous research [80]. 
The observed significant relationship between Herceptin treatment and higher 
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levels of FOR is interesting, and merits further exploration. It raises the question as 
to the perceptions that patients have around the meaning of being recommended 
this additional treatment. It is possible the findings relate to a further, unmeasured 
variable of total duration of treatment. Receipt of Herceptin treatment may extend 
the length of treatment, and it could be hypothesised that those who experience a 
longer treatment duration may have more difficulties adjusting to the ‘new normal’ 
of cancer survivorship. As Herceptin is a relatively new treatment, such questions 
have yet to be explored, and could be usefully addressed in future using qualitative 
approaches.   
The finding that levels of fear of cancer recurrence decreased with increasing time 
since diagnosis and completion of treatment is in contrast with evidence from [84], 
who reported that FOR persisted for the duration of their study (18 months) for 
those individuals with high levels at the point of cancer surgery. This discrepancy 
may be due to the fact that the mean time since treatment completion in the current 
study was 2.2 years, and participants were included up to 9 years post treatment. 
This may have meant that relative to Savard & Ivers’ study, a longer period of time 
had passed for participants during which FOR reduced. Indeed, two further studies 
found a similar pattern to the current findings of decreasing levels of FOR over time 
[85-86]. Neither study reported mean time since treatment completion, however for 
both sample the mean time since diagnosis was longer than within Savard & Ivers’ 
study [84]. Further work to explore the unique trajectory of FOR would be helpful, 
in order to identify the best time to introduce screening and intervention. An 
ongoing UK study by Hulbert-Williams and colleagues [87] will offer crucial further 
information from a longitudinal perspective to inform this. This is an important 
consideration in light of current discord over establishing clinically meaningful 
levels of FOR [88]. Further work will be required to ensure intervention approaches 
in clinical practice achieve an effective balance between prevention of the 
development of long term symptom burden, while not pathologizing natural 
reactions to life threatening disease and allowing for the natural decline in FOR over 
time in a supported environment where required. In line with acceptance-based 
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approaches, considering the ways in which individuals relate and respond to FOR 
could contribute usefully to decisions around when best to offer intervention and 
for whom. In addition, successfully addressing processes such as cognitive fusion 
and living in accordance with values could allow acceleration of the natural process 
of habituation and reductions in FOR. 
Despite the existence of these confounding variables, it is important to note that the 
mediating effects of cognitive fusion and valued living were evident even when 
they were controlled for within the analyses. This suggests the importance of 
considering these processes over and above factors such as time since treatment 
completion and age, in assessing individuals relative risk of poor outcomes [80].  
Limitations of the Current Study 
There are several limitations which should be considered when interpreting the 
results of the study. Firstly, participants were recruited mainly via third sector 
cancer support organisations. Such services provide emotional and practical 
support to individuals who are presumably open to addressing such issues. It is 
therefore possible that they were, as a sample, both more distressed and or more 
psychologically flexible than the cancer survivor population.  This has the potential 
to somewhat limit the generalisability of the findings to other cancer survivor 
populations.  
Secondly, the recruited sample consisted mostly of female breast cancer patients, 
who were relatively young in comparison to general cancer populations.  The over 
representation of breast cancer patients in psycho-oncology research has been 
reported by many authors and in part can be accounted for by the fact that breast 
cancer represents the highest proportion of cancer diagnoses within the UK. Of 
relevance to the current study, there are also many more third sector support 
services specifically aimed at breast cancer than other cancer types. It may therefore 
be the case that breast cancer patients are more likely to engage in third sector 
support services and as a result more likely to be exposed to research recruiting 
within these settings. In any case, as has been highlighted by others, it is important 
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for future research to make efforts to specifically target harder to reach cancer 
groups, to ensure that their experiences and needs are considered and contribute to 
our understanding of the emotional experiences of cancer and the development of 
novel interventions. On the other hand, in relation to the specific topic of fear of 
cancer recurrence, previous reports have not found meaningful differences in levels 
of distress and FOR between different cancer types [14]. It is hoped therefore that 
the present results are generally reflective of mixed cancer survivor populations.     
In relation to potential methodological limitations of the research, it is of note that 
the study was cross sectional in nature. As a result, although the use of mediation 
analyses provides some evidence to suggest potential processes linking FOR with 
the outcomes of interest, causation cannot be established. Larger scale longitudinal 
research would be helpful to elucidate this further. It is also recognised that due to 
the remote nature of recruitment methods, information around eligibility and 
clinical cancer related data was collected via self-report, rather than from validated 
medical sources, potentially reducing its reliability. However, several safeguards 
were put in place to try to mitigate this risk, including advertising the study via 
well-known and respected cancer support organisations, and requesting a 
minimum level of detail from participants regarding cancer related information, in 
order to cross validate their eligibility for the study. Furthermore, it was necessary 
to balance the risk of reduced reliability with using recruitment strategies which 
were feasible for accessing harder to reach populations equitably. Finally, it is noted 
that the current study did not collect information on time since participants’ last 
contact with their medical team or GP in relation to their cancer. Although to some 
extent this information can be estimated from the time since treatment was 
completed, failure to specifically capture these details means it was not possible to 
consider the potential influence of this on levels of FOR and distress at the time of 
completion of the survey. It may be important for future studies to consider 
collecting information on these variables.  
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Despite exploring multiple avenues to maximise recruitment using a range of 
methods, the number of participants recruited to the study was lower than 
expected. The rate of recruitment of 3.6 participants per month was largely in 
keeping with reported median rates of recruitment to oncology RCTs in the UK [89]. 
However, with around 180 paper questionnaire packs made available via cancer 
organisations and over 3,500 individuals having viewed the information page for 
the online survey, the total of 75 completed responses is low. It is not possible to 
establish an exact recruitment percentage for comparison, as many individuals who 
viewed the survey may not have been eligible to take part. However, it is of note 
that another recent cross-sectional study with cancer survivors within the secondary 
care setting in the UK reported substantially higher recruitment rates (26%; [80]). It 
is possible that the topic itself may have been a barrier to completion, as clinicians 
and researchers alike have noted anecdotally that fear of cancer recurrence can be a 
challenging topic to engage cancer survivors in conversation. Within the UK, the 
recent introduction of post cancer treatment summaries [90] may go some way to 
address this, in addressing patient misunderstandings about risk of recurrence, and 
providing an opportunity to initiate discussion of the topic. Nevertheless, this issue 
has obvious implications for the success of future screening and intervention 
approaches on the topic, and it would also therefore be beneficial for qualitative 
approaches to address the question of how best to engage survivors in discussion 
around this topic and current barriers to this.   
 
Current Barriers to FOR Research 
There are a number of issues currently highlighted with the research around fear of 
cancer recurrence, which if addressed could help to advance scientific 
understanding of the phenomenon and the development of effective interventions. 
One such area is the considerable inconsistency in current terminology surrounding 
cancer survivorship. There are significant variations within both clinical and 
research settings with regards to what is meant by terms such as ‘cancer survivor’, 
‘successful treatment’, and ‘disease free’. This poses obvious difficulties in assessing 
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survivorship research, where comparisons between studies employing differing 
conceptualisations and definitions of survivorship can be challenging. Furthermore, 
for many patients themselves, cancer may be conceptualised as a chronic illness, 
and the term cancer survivor may not always be used or accepted. This is an 
important concept to be clarified by future research, particularly in light of evidence 
pointing to the existence of specific time points at which distress can emerge [3-5]. 
In practical terms, future survivorship research would benefit from specifying time 
from end of primary treatment to entry into the study, something which is currently 
not always stated [91]. Not only is this important to clarify in terms of ensuring 
meaningful research comparisons, but clinically, clarification of terminology may 
have a direct influence on distress and FOR in terms of affecting patient perceptions 
around disease status and likely prognosis. 
Another area which has recently begun to be addressed, is that of consensus around 
the theoretical underpinning and definition of FOR, and agreed standard tool for its 
measurement [30, 88, 92]. Currently, a range of measurement tools have been 
utilised across research into FOR, limiting the degree to which research can reliably 
be compared and amalgamated. Perhaps more importantly, current differences in 
whether or not FOR is defined in terms of its severity or, more commonly, in a 
multidimensional way incorporating both its severity and consequences, have 
fundamental implications for the utility and purpose with which the tool is used 
[88]. In line with the theoretical argument proposed by the current study, it could be 
argued that levels of severity (which could be conceptualised as the content and 
frequency with which the fears are experienced) should be considered as distinct 
from the consequences of such fears, which are likely to be influenced by a number 
of mediating factors.    
It is encouraging that FOR has been increasingly recognised in recent years as an 
important concern for cancer survivors, and that this has been reflected in a surge in 
research on the topic and the development of novel interventions. However, there is 
still further work to be done to secure its place on the agenda for survivorship care 
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planning. Two recent global reports recognised it as an important issue contributing 
to the development of mood disturbance among cancer survivors, and suggested 
further exploration was required to determine when it becomes a clinically 
significant issue [93-94]. However, neither of these reports produced any specific 
recommendations in terms of identifying and responding to FOR.  
With the challenges around defining and measuring FOR, as well as engaging 
patients in conversations around the topic, there is much to be done before 
screening and interventions can be implemented within clinical settings. However, 
it is important that consideration be given around how such developments could 
eventually be integrated into cancer care within the UK. It could be argued that 
specialist oncology services may have the most expertise and be the most 
appropriate setting to address needs around FOR. On the other hand, once patients 
leave the routine cancer follow up system it is generally primary care services who 
are the gatekeepers of and providers of care. This issue is discussed in a recent 
interesting paper by [95], where it is suggested that patients themselves have 
expressed a wish for issues such as FOR to be discussed and supported via primary 
care services. Although this paper presents an American perspective on the issue, it 
raises important questions to be discussed. 
Summary and Conclusions  
The main aim of this study was to explore the role of psychological flexibility in 
mediating the relationship between FOR and adjustment difficulties (distress and 
QOL). It was hypothesised that for individuals with increased levels of FOR, 
relating to their fears with less psychological flexibility would lead to increased 
levels of distress and reduced QOL. The secondary aim of the study was to 
investigate the relative performance of an overall measure of psychological 
flexibility versus process level measurement in predicting these relationships.  
In summary, results do not support the hypothesis that the direct relationship 
observed between FOR and distress and QOL is mediated by levels of psychological 
flexibility. However, two of the individual processes measured within the concept 
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of psychological flexibility, fusion to thoughts and valued living, did significantly 
mediate these relationships. In other words, FOR appears to lead, in part, to poorer 
outcomes via its influence on increased fusion to thoughts, and decreased living in 
accordance with values. Whilst overall, these findings do not specifically offer 
support to the application of the psychological flexibility model within 
interventions in cancer survivorship, they do highlight the potential benefit of 
considering the way in which individuals relate to their thoughts as an important 
avenue for the development of screening and targeting of interventions. Specifically, 
successful interventions may be aimed at helping individuals develop a less fused 
relationship with their FOR and promoting value based behaviour. Further 
longitudinal studies would be helpful to test the replicability of these findings, with 
larger samples of mixed cancer patients. One such study which is currently ongoing 
[87] may take an important further step towards the successful of targeted effective 
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Appendix 1. PICO table used to guide question 
definition and study selection process 
 
 Inclusion Exclusion 
Population Humans, males & females  
 
Cancer survivors, defined 
as - individuals who have 
had a diagnosis of any 
type of cancer and have 
completed primary cancer 






Studies which recruit 
patients towards the end 
of treatment will be 
included if participants 




Studies which include 
both post treatment 
survivors and those in 
current treatment will be 
included only if the 
results are reported 
separately. 
 
Individuals who were 18 
years and older at the 
time of diagnosis, no 
upper age limit   
Individuals newly 
diagnosed with cancer or 
currently undergoing 






Individuals who have not 
received a cancer 
diagnosis.  
 
Adult survivors of 
paediatric cancer 
 
Family members of cancer 
patients (who may be 
referred to as cancer 






Interventions which have 






(MBCT). Yoga studies 
only where clear 
component consistent 
with mindfulness practice.  
 
Interventions that target 
psychological wellbeing 
following cancer 
treatment e.g. aiming to 
reduce emotional distress 
and/or increase QOL or 





researchers; mental health 
clinicians or nursing staff 
with relevant training and 
experience. 
 
Delivered face to face, via 
the internet or other 
technology mediums 
 
Group and individual 
settings 
 
Self- help interventions, 




Interventions without an 
explicit mindfulness 
component e.g. yoga 
practice or physical 
exercise techniques  
 
Studies that are not 
directly testing a 
psychological 
intervention, rather a 




purely of information 
giving, with no 
psychological element, e.g. 




purely of peer support, 





with no active supportive 
intervention component 
delivered (e.g. booklet 








intervention materials and 
work through these in an 
interactive supported 
manner via the internet or 
other technology medium 
interventions delivered to 
the partners/family 
members of cancer 
survivors, rather than the 
survivor themselves  
Comparator Studies including one or 
more comparison groups: 
Comparisons might 
include other non-active 
intervention control not 
including psychological 
intervention element (e.g. 
simple information 
giving), wait list control, 
or TAU 
 
Outcomes Any study which 




Distress (e.g. anxiety 
and/or depression) 
Fear of recurrence 
(measured using specific 
fear of recurrence 
measure) 
Positive psychological 
processes (e.g. post 
traumatic growth) 
 
Only studies which 
measured these outcomes 
using established 
validated questionnaires 
will be included 
 
Studies which collect 
outcome measures on at 
least two occasions, pre-
Studies which report only 
qualitative outcomes only 
 
Studies which collect 
outcome measures only at 
one time point 
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intervention and post 
Study Design Only studies employing a 
Randomised Controlled 




controlled / longitudinal 
pre-post designs, 
protocols of ongoing 
research, qualitative 
studies, commentaries, 
conference abstracts / 
posters, editorials, reviews 
of the literature, case 




Appendix 2. Operationalisation of Quality Ratings 
 























































































































Where blinding of 
outcome assessors 
to allocated 
intervention was in 
place and unlikely 
to have been 




















Where a study 
protocol is available 




to this review) have 
been reported. OR 
where a protocol is 
not available but it 
is clear that all pre-
specified outcomes 
















approach using e.g. 
date of birth, 









Where no blinding 
of outcome 
assessors took place 
and outcomes were 
collected by 
individuals 
involved in the 
















has not been 
carried out 
(e.g. per 




Where one or more 
of the pre-specified 
outcomes (relevant 
to this review) has 
not been reported, 
or have been 
reported using 
measurements or 
analysis that were 
not pre-specified. 
Or where one or 




good reason for 
their inclusion. Or 
where the study 
fails to report 
outcomes which 
would be expected 









reported to assess 
whether or not 
randomisation 






reported to assess 





well or poorly 
assessed 














not reported.  
Where it is not 
clear whether 








or not reporting has 
been well or poorly 
addressed 
 

































































Where the main 
characteristics of 
the sample have 
Where an a priori 
power calculation 















been described in 
sufficient detail to 
allow it to be 
established that the 
intervention and 
control groups are 
similar in 
characteristics at 
the start of the trial 




been controlled for 
in the analysis as 
covariates. 
determine sample 
size, taking into 
account assumed 
drop-out rate, and 
where the study 
was at least 0.80 
powered OR where 
the power 
calculation did not 
take into account 
assumed drop out 
but was at least 0.80 
powered with 
actual drop-out rate 
relevant training 
and or experience 
in relation to the 
intervention being 
delivered. This 
may include a 
specified training 


























Little or no 









Where the main 
characteristics of 
the sample have 
been described in 
sufficient detail to 
allow it to be 
established that 
there are 
Where no a prior 
power calculation 
was conducted to 
determine sample 
size. Or where an a 
priori sample size 
calculation was 
reported, but the 
Where no training 
or experience 
relevant to the 
intervention being 
delivered has 
been provided to 
the intervention 
facilitator(s) or 































control groups at 
the start of the 
study, which have 
not been controlled 
for in the analysis. 
 







described is not 








risk of bias. 
Conclusions 
may change 
in the light 
of further 
studies. 
Unable to say 
(?) 





the sample to 
identify that both 
groups are similar 
at the start of the 
study 
Where power was 




determine if it was 
well or poorly 
addressed 








been well or 
poorly established 











fidelity has not 
been addressed 



































Appendix 3. Quality Criteria Ratings of Reviewed Studies 
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Appendix 5. Patient Information Leaflet 
 
 
                                        
Participant Information Sheet                   
LIVING WELL AFTER CANCER TREATMENT  
 
Please read the following information carefully before you decide whether or not to take 
part in this research study.  
What is the purpose of the study? 
Many cancer survivors who have completed cancer treatment experience fears about their 
cancer coming back, sometimes known as fears of recurrence. For some people, these fears 
can cause significant distress and negatively impact on their day to day wellbeing. However 
this is not the case for everyone and for some people, they have less of a negative impact. 
     
The aim of this study is to investigate how psychological factors influence how cancer 
survivors are impacted by fears of recurrence. In particular, we are interested in the way 
that people deal with their feelings, thoughts and fears. It is hoped that findings from this 
study will help improve our understanding of fears of cancer recurrence, and develop 
interventions aimed at helping reduce their negative impact. 
Who is carrying out this research? 
This study is being carried out as part of a Clinical Psychology Doctorate thesis at the 
University of Edinburgh. It has been reviewed and approved by the University Of Edinburgh 
School of Health in Social Science Research Ethics Committee, and the South East Scotland 
Research Ethics Committee 01. 
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Who can take part in the study? 
We are looking for individuals who fit the following criteria to take part in the study: 
Aged 18 or over 
Able to read in English 
Have received a diagnosis of cancer 
Have completed curative cancer treatment, including surgery; chemotherapy; radiotherapy; 
or any combination of these treatments, and have no evidence of any current cancer. 
Note: (Breast and prostate cancer patients receiving ongoing hormonal and/or Herceptin 
treatments are eligible to take part)  
 
In total, it is hoped that at least 145 people will participate in this study. Cancer survivors 
are being informed about the study and invited to take part via cancer support related 
services and relevant social media. The study is being supported by Maggie’s Centres and 
online support centre. 
Unfortunately, for insurance reasons we are not able to recruit participants to this study 
from the USA. 
Do I have to take part?  
It is up to you to decide whether or not to take part. The decision you make about taking 
part will not affect your attendance or use of Maggie’s Centres in any way.  
What does taking part involve? 
It involves completing a set of 8 questionnaires, on one occasion. The questionnaires will 
ask you about your experience of fears about cancer recurrence; questions about how you 
think, feel and behave in your day to day life; and questions about distress and quality of 
life. The questionnaires can be completed online or, if you prefer, using pen and paper. If 
you choose this option you will be provided with a pre-addressed envelope to return the 
questionnaires.   
By completing the study questionnaires online, or completing and returning them on paper, 
we will assume you consent to take part in the study. You can choose to exit the study at 
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any time, without giving a reason. However, as all the information collected will be non-
identifiable, we will not be able to delete the answers you have already provided. Following 
your completion of the one-off questionnaire survey you will not be contacted again by the 
research team. 
Will my taking part in the study be confidential? 
Participation is completely anonymous. You will be asked to answer a few questions 
providing basic information about your cancer (such as the site of your cancer; time since 
your diagnosis; and type of treatment you received). This information is requested to check 
that you meet criteria for taking part in the study, and will not be used to identify you in 
any way.  
What will happen to the information I provide? 
If you choose to complete your questionnaires online, your answers will be collected using 
a survey tool, hosted by the University of Edinburgh, which will ensure your data is kept 
securely. Your survey answers will be downloaded and stored on a secure password 
protected computer. Your e-mail address will not be stored.  
If you choose to complete your questionnaires on paper, paper questionnaires will be 
stored within a locked filing cabinet. These will be stored for a period of up to 5 years and 
then destroyed.  
 What are the possible benefits of taking part? 
There is unlikely to be any immediate benefit to you in taking part in the study. However, 
you will be providing valuable information, which it is hoped will be used to develop new 
ways of helping cancer survivors to deal with fears of recurrence. In addition, sometimes 
people say that reflecting on their experience while completing the questionnaires can help 
them to make sense of it. 
What are the possible risks and disadvantages of taking part? 
It is possible that completing some of the questionnaires may bring up some unpleasant 
feelings or thoughts for you. If there are any questions which you would prefer not to 
answer, you may leave them blank, or choose the ‘prefer not to answer’ option if you are 
completing the questionnaires online.  
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If you would like to speak to someone for support on any issues arising from completing the 
questionnaires, there are a number of services that are available to provide support, which 
you will find details of when you exit the survey. 
What will happen after the research is completed? 
Once the study is complete, the data will be analysed and the findings will be presented for 
publication in a scientific journal and submitted for presentation at a national cancer 
research conference. A summary of findings from the study will also be published on the 
Maggie’s online centre website.  You will not be identifiable from the information included 
in the published findings.  
If you have any further questions 
If you would like to contact the lead researcher for further information, or if you have any 
queries, you can do so using the following contact details: 
Kate Randell 
Trainee Clinical Psychologist 
University of Edinburgh 
School of Health in Social Science 
Teviot Place, Edinburgh 
E-mail: k.randell@sms.ed.ac.uk  
For general information about taking part in research, you can contact:  
Dr Ethel Quayle 
Director of Research and Knowledge Exchange – School of Health 
22, Buccleuch Place, Edinburgh 
To speak to someone who knows about this research study, but is not directly involved, you 
can contact: 
Dr Emily Newman 
University of Edinburgh 
Department of Health in Social Sciences 




If you wish to make a complaint about the study, please contact the University of 
Edinburgh’s Research Governance team via email at: researchgovernance@ed.ac.uk 
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and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of 
Helsinki and its later amendments or comparable ethical standards. 
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independent ethics committee or institutional review board explicitly approved the doubtful aspects of the 
study. 
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Ethical approval: “All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 
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2) Statement on the welfare of animals 
The welfare of animals used for research must be respected. When reporting experiments on animals, 
authors should indicate whether the international, national, and/or institutional guidelines for the care 
and use of animals have been followed, and that the studies have been approved by a research ethics 
committee at the institution or practice at which the studies were conducted (where such a committee 
exists). 
For studies with animals, the following statement should be included in the text before the References 
section: 
Ethical approval: “All applicable international, national, and/or institutional guidelines for the care and 
use of animals were followed.” 
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If applicable (where such a committee exists): “All procedures performed in studies involving animals 
were in accordance with the ethical standards of the institution or practice at which the studies were 
conducted.” 
If articles do not contain studies with human participants or animals by any of the authors, please select 
one of the following statements: 
“This article does not contain any studies with human participants performed by any of the authors.” 
“This article does not contain any studies with animals performed by any of the authors.” 
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authors.” 
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is incapable) gave written informed consent for publication. Complete anonymity is difficult to achieve in 
some cases, and informed consent should be obtained if there is any doubt. For example, masking the eye 
region in photographs of participants is inadequate protection of anonymity. If identifying characteristics 
are altered to protect anonymity, such as in genetic profiles, authors should provide assurance that 
alterations do not distort scientific meaning. 
The following statement should be included: 
Informed consent: “Informed consent was obtained from all individual participants included in the 
study.” 
If identifying information about participants is available in the article, the following statement should be 
included: 
“Additional informed consent was obtained from all individual participants for whom identifying 
information is included in this article.” 
RESEARCH DATA POLICY 
A submission to the journal implies that materials described in the manuscript, including all relevant raw 
data, will be freely available to any researcher wishing to use them for non-commercial purposes, without 
breaching participant confidentiality. 
The journal strongly encourages that all datasets on which the conclusions of the paper rely should be 
available to readers. We encourage authors to ensure that their datasets are either deposited in publicly 
available repositories (where available and appropriate) or presented in the main manuscript or 
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additional supporting files whenever possible. Please see Springer Nature’s information on recommended 
repositories. 
List of Repositories 
Research Data Policy 
General repositories - for all types of research data - such as figshare and Dryad may be used where 
appropriate. 
Datasets that are assigned digital object identifiers (DOIs) by a data repository may be cited in the 
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as DOIs and accession numbers) for relevant datasets must be provided in the paper. 
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Research Data Policy Frequently Asked Questions 
Data availability 
The journal encourages authors to provide a statement of Data availability in their article. Data availability 
statements should include information on where data supporting the results reported in the article can be 
found, including, where applicable, hyperlinks to publicly archived datasets analysed or generated during 
the study. Data availability statements can also indicate whether data are available on request from the 
authors and where no data are available, if appropriate. 
Data Availability statements can take one of the following forms (or a combination of more than one if 
required for multiple datasets): 
1. The datasets generated during and/or analysed during the current study are available in the [NAME] 
repository, [PERSISTENT WEB LINK TO DATASETS] 
2. The datasets generated during and/or analysed during the current study are not publicly available due 
[REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable 
request. 
3. The datasets during and/or analysed during the current study available from the corresponding author 
on reasonable request. 
4.Data sharing not applicable to this article as no datasets were generated or analysed during the current 
study 
5. All data generated or analysed during this study are included in this published article [and its 
supplementary information files]. 
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